



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | |
|--|-----------|--|
| (51) International Patent Classification ⁶ : C07D 403/10, A61K 31/505, C07D 405/14, 403/14, 401/14 | A1 | (11) International Publication Number: WO 98/39328 (43) International Publication Date: 11 September 1998 (11.09.98) |
| (21) International Application Number: PCT/EP98/01051 (22) International Filing Date: 24 February 1998 (24.02.98) (30) Priority Data: 97103436.8 3 March 1997 (03.03.97) EP (34) Countries for which the regional or international application was filed: AT et al. (71) Applicant: F.HOFFMANN-LA ROCHE AG [CH/CH]; Grenzacherstrasse 124, CH-4070 Basle (CH). (72) Inventors: GUERRY, Philippe; In den Holeematten 2, CH-4102 Binningen (CH). HUBSCHWERLEN, Christian; Rue de la Gendarmerie, F-68200 Durmenach (FR). JOLIDON, Synèse; Stutzhalde 2, CH-4223 Blauen (CH). SPECKLIN, Jean-Luc; 2, rue des Faisans, F-68680 Kembs-Schaferhof (FR). WYSS, Pierre-Charles; Unterwartweg 27, CH-4132 Muttens (CH). (74) Agent: BRAUN, Axel; Grenzacherstrasse 124, CH-4070 Basle (CH). | | (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> |
| (54) Title: SUBSTITUTED 2,4-DIAMINOPYRIMIDINES <div style="text-align: center;"> <p>(I)</p> </div> (57) Abstract <p>The invention is concerned with compounds of general formula (I), wherein R¹ signifies lower-alkoxy, R² signifies hydroxy or lower-alkoxy, R³ signifies hydrogen, cyano, alkyl, alkenyl, cycloalkyl, aryl, heterocycyl, aralkyl, aryl-Q-alkyl, heterocyclalkyl or a group of the formula -(CH₂)_n-, Q signifies -SO-, R⁴, R⁵ each independently signify hydrogen, alkyl, aryl or heterocyclalkyl, R⁵ signifies hydrogen, alkyl, alkoxy, aryl or heterocycyl, or R⁴ and R⁵ together can form a group -(CH₂)_n-, and n is a whole number of 2 to 5, as well as pharmaceutically usable salts thereof; the use of these compounds and their salts as therapeutically active substances; medicaments based on these substances and their production; the use of these substances as medicaments and for the production of antibacterially-active medicaments; as well as the manufacture of the compounds of formula (I) and their pharmaceutically acceptable salts and intermediates for their manufacture.</p> | | |

FOR THE PURPOSES OF INFORMATION ONLY


Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | ML | Mali | TR | Turkey |
| BG | Bulgaria | HU | Hungary | MN | Mongolia | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MR | Mauritania | UA | Ukraine |
| BR | Brazil | IL | Israel | MW | Malawi | UG | Uganda |
| BY | Belarus | IS | Iceland | MX | Mexico | US | United States of America |
| CA | Canada | IT | Italy | NE | Niger | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NL | Netherlands | VN | Viet Nam |
| CG | Congo | KE | Kenya | NO | Norway | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NZ | New Zealand | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's Republic of Korea | PL | Poland | | |
| CM | Cameroon | KR | Republic of Korea | PT | Portugal | | |
| CN | China | KZ | Kazakhstan | RO | Romania | | |
| CU | Cuba | LC | Saint Lucia | RU | Russian Federation | | |
| CZ | Czech Republic | LI | Liechtenstein | SD | Sudan | | |
| DE | Germany | LK | Sri Lanka | SE | Sweden | | |
| DK | Denmark | LR | Liberia | SG | Singapore | | |
| EE | Estonia | | | | | | |

Substituted 2,4-diaminopyrimidines

5

The present invention is concerned with substituted 2,4-diamino-pyrimidines of the general formula



10

wherein

R¹ signifies lower-alkoxy;

R² signifies hydroxy or lower-alkoxy;

R³ signifies hydrogen, cyano, lower-alkyl, alkenyl, cycloalkyl, bicycyl, aryl, heterocyclyl, heteroaryl, aralkyl, aryl-Q-alkyl, heterocyclylalkyl or a group of the formula-CR⁴R^{4'}COR⁵;

15

Q signifies -SO- or SO₂;

R⁴, R^{4'} each independently signify hydrogen, alkyl, aryl or heterocyclyl;

20

R⁵ signifies hydrogen, alkyl, alkoxy, aryl or heterocyclyl, or

R⁴ and R⁵ together can form a group -(CH₂)_n-, and

n is a whole number of 2-5,

as well as pharmaceutically usable salts thereof.

- 5 The compounds of formula I are novel and possess valuable antibiotic properties. They can be used for the control or prevention of infectious diseases. In particular, they exhibit a pronounced antibacterial activity even against multiresistant, gram-positive strains and against resistant pneumococci and opportunistic pathogens such e.g. *Pneumocystis carinii*.
- 10 The compounds of formula I can also be administered in combination with known antibacterially-active substances and then exhibit synergistic effects. Typical combination partners are e.g. sulphonamides, with which the compounds of formula I or their salts can be admixed in various ratios.

- Objects of the present invention are compounds of formula I and their
- 15 pharmaceutically acceptable salts per se and for use as therapeutically active substances, medicaments based on these substances, optionally in combination with sulphonamides, and their production; the use of these substances as medicaments and for the production of antibacterially-active medicaments; as well as the manufacture of the compounds of formula I
- 20 and their pharmaceutically acceptable salts and intermediates for their manufacture.

- The terms "lower-alkyl" and "lower-alkoxy" embrace-chain or branched alkyl and, respectively, alkoxy groups which are optionally substituted by one or more substituents, such as, for example, methyl, ethyl,
- 25 n-propyl, isopropyl, n-butyl, isobutyl, tert.butyl, n-pentyl and n-hexyl; and, respectively, methoxy, ethoxy, n-propoxy, isopropoxy, n-butyloxy, isobutyl-oxy, and tert.butoxy. Suitable substituents for these alkyl and alkoxy groups are functional groups such as, for example, amino, dialkylamino, morpholino, piperidino, piperazino, hydroxy, halide, nitrile, thiocyanato, sulfato,
- 30 methylsulfanyl, oxo, carboxy, carbamino or carbalkoxy groups or substituents such as alkoxy, morpholinoalkoxy, piperidinoalkoxy. Methoxymethyl, hydroxymethyl, hydroxybutyl, dihydroxybutyl, 2-oxo-propyl, 3-propionaldehyde, perfluorohexyl and the like are examples of such substituted alkyl and alkoxy groups.

The term "alkenyl" embraces unsaturated hydrocarbon residues with up to 6 carbon atoms containing a double bond such as vinyl, allyl, butenyl and the like. The alkenyl chain is optionally substituted by one or more substituents, such as, for example, cyano and acryloyl.

- 5 The term "cycloalkyl" embraces cyclic alkyl groups with preferably 3-6 carbon atoms, which can be substituted with functional groups and substituents as mentioned under alkyl and alkoxy.

Examples for bicycyl groups are adamantyl or bicyclo[2.2.1]hept-2-endo- and/or 2-exo-yl.

- 10 The term "aryl" denotes 6-membered mono- or poly-nuclear aromatic groups with preferably 6-14 carbon atoms. Examples of such groups are phenyl, naphthyl, anthryl and phenanthryl, which can be substituted by one or more substituents. Suitable substituents for ether mentioned aryl groups are e.g. phenyl; lower-alkyl (e.g. methyl); substituted lower-alkyl (e.g. tri-
15 fluoromethyl, pentafluoro ethyl); C₃₋₆ cycloalkyl (e.g. cyclopropyl); hydroxy; cyano; thiocyanato; amino; hydroxyalkyl, optionally esterified with amino acids or sulphuric acid (such as, for example, 2-amino-propionic acid ester or 2-amino-5-guanidino-pentanoic acid ester); halogen (e.g. chlorine); lower-alkoxy (e.g. methoxy, n-butoxy); lower alkoxycarbonyl (e.g. methoxy-
20 carbonyl); di(lower alkyl)amino (e.g. dimethylamino, diethylamino); carbamoyl, mono- or di-lower-alkylcarbamoyl; lower-alkylsulphanoyl, (e.g. methylsulphanoyl); lower-alkylsulphonyl, (e.g. methanesulphonyl); sulphamoyl, N-mono- or di-lower alkylsulphamoyl; heterocyclyl, or with heterocyclyl-lower-alkyl.

- 25 The term "heterocyclyl" embraces in the scope of the present invention 4 to 6 membered rings with 1 to 3 N, O and/or S atoms such as, for example, cyclic lactones, cyclic lactames, ketals (such as, for example, 2-dimethyl-1, 3-dioxolan-yl), acetals (e.g. 1,3, dioxolan-2-yl or 1,3,-dioxan-2-yl); examples of such rings are morpholin-4-yl, 4-methyl-piperazin-1-yl, imidazol-1-yl,
30 thiazolyl and [1,2,4] triazol-1-yl, dithianyl, tetrahydropyranyl; the heterocyclic rings can be substituted with substituents described above for the aryl groups. Such substituents are especially lower-alkyl, lower-alkoxy, hydroxy, amino, hydroxyalkyl, aminoalkyl or oxo. Pyrrolidinone, methylpyrrolidinone and the like are examples of preferred substituted
35 heterocyclic rings.

The term "heterocyclyl-lower alkyl" embraces in the scope of the present invention heterocyclic rings which are linked via an alkyl residue. Preferred heterocyclyl-lower-alkyl units are e.g morpholin-4-ylmethyl, 4-methyl-piperazin-1-ylmethyl, imidazol-1-ylmethyl and [1,2,4]triazol-1-ylmethyl, dioxolan-4-yl-ethyl, pyrrolidinylmethyl, piperidinylmethyl and the like.

The term "heteroaryl" denotes in the scope of the present invention 5- or 6- membered, mono- or poly-nuclear heteroaromatic groups with preferably 5-13 carbon atoms and 1-4 hetero atoms, preferably nitrogen, oxygen and/or sulphur atoms. Furyl, pyranyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, oxazolyl, oxadiazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl are examples. These groups can also be linked with a fused ring, preferably a phenyl ring. Examples of such linked rings are, for example, benzopyranyl, benzofuranyl, indolyl and quinolinyl. The heteroaryl groups can be substituted, for example with substituents as described above for the aryl groups.

In formula I the group R^1 is preferably methoxy; R^2 is preferably hydroxy, lower alkoxy such as e.g. methoxy or ethoxy; or lower alkoxy substituted by lower alkoxy such as e.g. methoxymethoxy, lower alkoxy substituted by heterocyclyl such as e.g. morpholin-4-yl-ethoxy or lower alkoxy substituted by lower alkoxycarbonyl-lower alkyl, preferably methoxycarbonylmethyl.

Preferred lower alkyl groups R^3 are the following groups:

methyl (Ex. 1.32, 1.33, 2.11); ethyl (Ex. 2.13); propyl (Ex. 1.30, 1.31, 2.15, 2.16); 3-methyl-butyl (Ex. 2.17); tert. butyl (Ex. 1.23).

Preferred substituents for the lower alkyl residue R^3 are the following substituents:

hydroxy such as e.g. hydroxypropyl (Ex. 2.18), hydroxybutyl (Ex. 2.20), 3,4-dihydroxybutyl (Ex. 16);
methylsulfanyl such as e.g. methylsulfanylmethyl (Ex. 1.17);
fluor such as e.g. tridecafluorhexyl (Ex. 2.3);
carbamoyloxy such as e.g. carbamoyloxy-butyl (Ex. 2.21), carbamoyloxy-propyl (Ex. 2.22);
thiocyanato such as e.g. thiocyanatobutyl (Ex. 11);

-SO₄H such as e.g. sulfatobutyl (Ex.10.2) or heterocyclyl such as e.g. [1.3]dioxolan-2yl-ethyl (Ex. 2.23), [1.3]dioxolan-4yl-ethyl (Ex. 4).

Preferred substituents for the alkenyl-residue R³ are the following
5 substituents:
cyano such as e.g. cyanobutenyl (Ex.13.1);
acryloyl such as e.g. acryloylbutenyl (Ex.13.2).

Preferred lower cycloalkyl groups R³ are the following groups:
cyclopropyl (Ex 1.46 1.52, 1.53), cyclobutyl (Ex. 1.56), cyclopentyl (Ex.1.57),
10 cyclohexyl (Ex.1.60).

A preferred substituent for the cycloalkyl residue R³ is the oxo-group such as e.g. cyclopentanon (Ex.1.9), cyclohexanon (Ex.1.10).

Preferred heterocyclyl- or substituted heterocyclyl-residues R³ are:
dithian-2-yl (Ex. 1.49) or tetrahydropyran-2-on 1 (Ex. 1.14).

15 Examples for the group "aryl -Q-alkyl" are: phenylsulfonylmethyl (Ex. 1.69) or Phenylsulfinylmethyl (Ex. 2.5).

Examples for the group "CR⁴R^{4'}COR⁵" are: methylcarbonylmethyl (Ex.1.11), methoxycarbonyl(dimethyl)methano CH₃-CO-C(CH₃)₂- (Ex.1.12), hydroxycarbonyldimethylmethano (-C(CH₃)₂-CO-OH (Ex. 7),
20 phenylcarbonyl-methyl (Ex.1.13), phenylcarbonyl(methyl)methyl (Ex.1.15), furanylcabonyl-methyl (Ex.1.16) or morpholinylcarbonyloxybutyl (Ex. 2.19).

Preferred aryl groups R³ are phenyl or biphenyl, most preferred phenyl.

The phenyl residue is optionally mono, di-or tri substituted by the
25 following groups:
lower alkyl such as e.g. methyl (Ex. 1.19, 1.22, 1.25, 1.40, 1.41), ethyl (Ex. 1.20), butyl (Ex. 1.3), tert. butyl (Ex. 1.18);
substituted lower alkyl such as e.g. hydroxymethyl (Ex. 2.6, 2.8, 2.9, 2.12, 3.3, 8.3), hydroxy-ethyl (Ex. 1.68, 2.12), methoxymethyl (Ex. 1.71), trifluormethyl
30 (Ex. 1.58), dimethylaminomethyl (Ex. 1.7), diisopropylamino-methyl (Ex. 1.72), 2-aminopropionylmethyl (Ex. 9.1), carbamoyloxymethyl (Ex. 2.14);
lower alkoxy, preferably methoxy (Ex. 1.62, 32.6);
halogen, preferably fluoro (Ex. 2.1, 2.2), chloro (Ex. 1.73);

- methylsulfanyl (Ex. 1.47, 1.54, 1.55);
dimethylamino (Ex. 1.38);
dimethylamino sulfonyl (Ex. 1.6, 1.70);
cyano (Ex. 1.64);
- 5 hydroxy (Ex. 2.7, 2.10);
lower alkoxy such as e.g. methoxy (Ex. 1.61, 32.3);
substituted lower alkoxy such as e.g. hydroxyethoxy (Ex. 32.11),
trifluoromethoxy (Ex. 1.21), 1-ethoxy-ethoxy (Ex. 1.35), 2-ethoxy-ethoxy
(Ex. 1.39);
- 10 lower alkoxy-carbonyl such as e.g. tert. butoxy carbonyl (Ex. 1.65);
heteroaryl such as e.g. pyrrol-1-yl (Ex. 1.42), furan-2-yl (Ex. 1.28, 1.29, 1.4,
3.2, 8.2), thiazol-2-yl (Ex. 1.5);
heterocyclyl-lower alkyl such as e.g. 4-methyl-piperazin-1-ylmethyl (Ex.
1.75), 4-morpholin-4-yl-methyl (Ex. 1.76).
- 15 Preferred heteroaryl groups R^3 are pyridyl (Ex. 1.51, 1.2, 32.8)
pyrimidinyl, thiophen-2-yl (Ex. 1.66), 5,6-dihydro-4H-pyran-2-yl (Ex. 1.24),
[1,3]dioxolo[4,5-b]pyridin-6-yl (Ex. 32.13).

The heteroaryl groups R^3 is optionally mono, di-or tri substituted by the following groups:

- 20 lower alkyl such as e.g. methyl (Ex. 1.37, 1.43, 1.44, 1.48, 1.67, 1.8, 32.1, 32.2,
32.432.5), ethyl (Ex. 34.1);
substituted lower alkyl such as e.g. hydroxymethyl (Ex. 32.7), hydroxy-1-
methyl-ethyl (Ex. 1.78);
halogen, preferably chloro (Ex. 1.59), bromo (Ex. 32.9);
- 25 lower alkoxy such as e.g. methoxy (Ex. 1.74, 32.10, 32.12);
substituted lower alkoxy such as e.g. methoxy-ethoxy (Ex. 32.15), methoxy-
ethoxy-ethoxy (Ex. 32.16), hydroxy-ethoxy (Ex. 32.14), hydroxypropoxy (Ex.
32.17), 2-morpholin-4-yl-ethoxy (Ex. 32.19), dimethylamino-ethoxy (Ex. 32.20);
benzyloxy (Ex. 32.18);
- 30 dimethylamino (Ex. 1.50);
amino-carbonyl (Ex. 34);
tert. butyl amino carbonyl (Ex. 1.80);
heterocyclyl such as e.g. morpholin-4-yl (Ex. 1.79).

- Preferred compounds of formula I are those in which R^1 and R^2 signify
- 35 lower-alkoxy, especially methoxy; R^3 signifies phenyl, or substituted phenyl
or furyl, or lower-alkoxy. The compounds of formula I in which R^3 is

different from hydrogen can be present in racemic form or as the R- or S-enantiomer. Examples of preferred compounds of formula I are:


- A: (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-(1-phenyl-1H-phthalazin-2-yl)-propenone; (Example 1.1.)
- 5 B: (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-(1-furan-2-yl-1H-phthalazin-2-yl)-propenone; Example 1.4.)
- C: (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-(4-hydroxymethyl-phenyl)-1H-phthalazin-2-yl]-propenone (Example 2.6.)
- 10 D: (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-(4-hydroxy-phenyl)-1H-phthalazin-2-yl]-propenone (Example 2.7.)
- E: (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-(1-ethyl-1H-phthalazin-2-yl)-propenone (Example 2.13.)
- 15 F: (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-(4-hydroxy-butyl)-1H-phthalazin-2-yl]-propenone (Example 2.20.)
- G: (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-(1-propyl-1H-phthalazin-2-yl)-propenone; (Example 2.15)
as well as pharmaceutically usable salts of these compounds.
- 20 Furthermore, compounds of formula I are preferred wherein R³ is pyridin-yl or pyrimidinyl optionally substituted by lower alkyl such as e.g
- H: (E)-(R)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-(6-methyl-pyridin-3-yl)-1H-phthalazin-2-yl]-propenone (Example 1.43);
- I: (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-(6-methyl-pyridin-3-yl)-1H-phthalazin-2-yl]-propenone (Example 1.48),
- 25 J: (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-(6-ethyl-pyridin-3-yl)-1H-phthalazin-2-yl]-propenone (Example 34.1),

K: (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-(2-methyl-pyrimidin-5-yl)-1H-phthalazin-2-yl]-propenone
(Example 32.5).

The compounds of formula I form pharmaceutically acceptable acid
5 addition salts with organic and inorganic acids. Examples of acid addition
salts of compounds of formula I are salts with mineral acids, for example
hydrohalic acids, such as hydrochloric acid, hydrogen bromide and
hydrogen iodide, sulphuric acid, nitric acid, phosphoric acid and the like,
salts with organic sulphonic acids, for example with alkyl- and aryl-
10 sulphonic acids such as methanesulphonic, p-toluenesulphonic, benzen-
sulphonic acid and the like, as well as salts with organic carboxylic acids,
for example with acetic acid, tartaric acid, maleic acid, citric acid, benzoic
acid, salicylic acid, ascorbic acid and the like.


The compounds of formula I and their pharmaceutically acceptable
15 salts can be manufactured in accordance with the invention by

(a) reacting a compound of the general formula



wherein R¹ and R² have the above significance and Y signifies a
leaving group,

20 with a compound of the general formula



wherein R³ is as defined above,

or

(b) if desired, functionally modifying reactive groups present in the
25 reaction product,

or

c) converting a compound of formula I into a pharmaceutically acceptable salt.


In order to manufacture end products of formula I in accordance with
5 process variant a) of the process in accordance with the invention, a
so-called "Heck reaction" is carried out by e.g. reacting a starting compound
of formula II in which the leaving group Y represents, for example,
bromine, iodine, methanesulphonyloxy, trifluoromethanesulphonyloxy,
benzenesulphonyloxy or p-toluenesulphonyloxy with a compound of general
10 formula III. Preferably, an inert organic solvent, e.g. dioxan, tetrahydro-
furan, N,N-dimethylacetamide or N,N-dimethylformamide, is used. The
reaction is preferably effected in the presence of a base such as alkali metal
carbonate or hydrogen carbonate, e.g. potassium carbonate or sodium
hydrogen carbonate, and/or a tertiary amine, e.g. in a tri(lower alkyl)amine
15 such as triethylamine, tri-n-butylamine or N-ethylpiperidine, and together
with a catalyst, preferably a palladium complex, such as palladium(II)
acetate, bis(triphenyl-phosphine) palladium(II) dichloride, bis(triphenyl-
phosphine)palladium(II) diacetate, tetrakis-triphenylphosphine palladium,
or copper(I) iodide and triphenylphosphine or tri-o-tolylphosphine, optionally
20 with the addition of a phase transfer catalyst such as a tetraalkylammonium
salt, e.g. tetrabutylammonium bromide. The temperature of the "Heck
reaction" preferably lies in the region between about 40°C and the boiling
point of the reaction mixture.

If desired, reactive groups present in the reaction product can be
25 functionally modified in accordance with variant b) of the process in
accordance with the invention. For example, in reaction products of
formula I groups R³ which contain alcohol functions can be transformed
into an ester.

The manufacture of the salts of the compounds of formula I in
30 accordance with variant c) can be effected in a manner known per se, e.g. by
reacting a compound of formula I with an organic or inorganic acid,
conveniently in a solvent such as acetone, ethanol, methanol or water.

The compounds of formula III can be obtained in accordance with the
invention by

35 a) reacting a compound of the general formula



in which R^3 has the above significance


with a reactive acrylic acid derivative.

Examples of reactive acrylic acid derivatives are the acid halides,
5 especially the acid chloride, reactive amides, such as, for example, the
imidazolidine, and mixed anhydrides. The acylation in accordance with the
invention can be carried out in an inert solvent, e.g. a hydrocarbon such as
benzene or toluene, a chlorinated hydrocarbon such as chloroform or
methylene chloride, or an ether such as dioxan or tetrahydrofuran, in the
10 presence of a base, e.g. an amine such as pyridine or triethylamine (which
can simultaneously serve as the solvent). The reaction temperature is not
critical. The reaction is conveniently performed at temperatures between
0°C and 50°C, especially at 0°C to 30°C;

or, especially in the case of compounds of formula III in which R^3 signifies a
15 group of the formula $-CR^4R^4COR^5$, by

b) reacting a phthalazine in accordance with the following Reaction
Scheme with a silyl enol ether of formula V of an enamine of formula VI in
the presence of a reactive acrylic acid derivative such as, for example, the
acid halide:

Reaction A



wherein


- $R^4, R^{4'}$ each independently signify hydrogen, alkyl, aryl or
 5 heterocyclyl,
 R^5 , signifies hydrogen, alkyl, alkoxy, aryl or hetero-cyclyl,
 or
 R^4 and R^5 together can form a group $-(CH_2)_n-$,
 n is a whole number of 2 to 5,
 10 R^6-R^7 signify lower alkyl,
 and R^6 and R^7 in the case of enamines of formula VI can also
 together form a ring,
 X signifies a halogen atom such as e.g. chlorine or
 bromine.

- 15 This reaction is preferably effected in inert solvents such as ether or in
 chlorinated hydrocarbons at temperatures of -20°C to $+20^\circ\text{C}$ with subsequent
 hydrolysis of the reaction product at 0 to 50°C .

The compounds of formula IV can be prepared in accordance with the
 following Reaction Scheme

20

Reaction B



wherein

R³ has the above significance and

M signifies Li, Na, MgBr, MgCl or MgI.

5 This reaction is preferably effected in a temperature range of -80°C to 20°C. An open-chain or cyclic ether such as diethyl ether or tetrahydrofuran is preferably used as the solvent.

As mentioned earlier, the compounds of formula I and their pharmaceutically acceptable salts possess valuable antibacterial properties.
10 They are active against a large number of pathogenic microorganisms such as e.g. Staphylococcus aureus, Pneumocystis carinii, Streptococcus pneumoniae etc. by virtue of their activity in inhibiting bacterial dihydro-folate reductase (DHFR). The inhibition of this enzyme was taken as a measurement of the antibacterial activity. It is determined by the method of
15 D.P. Bacanari and S.S. Joyner (Biochemistry 20, 1710 (1981)) ; see also P.G. Hartman et al., FEBS Letters 242, 157 (1988).

The IC₅₀-values (concentration at which the enzyme is inhibited by 50%) are determined by means of a graph.

The following Table contains inhibitory concentrations determined for
20 representative members of the class of compound defined by formula I and determined in the above test. The IC₅₀ values (μM) against the purified DHFR of the reference strain S. aureus ATCC 25923, as well as against the purified DHFR of the multiresistant strain S. aureus 157/4696 are given. The third column shows IC₅₀ values (μM) against the purified DHFR of the
25 multiresistant strain Streptococcus pneumoniae 1/1. The inhibition constants of trimethoprim are also given as a comparison.

| Example | S.aureus ATCC25923 | S.aureus 157/4696 | S.pneumoniae 1/1 |
|--------------|-----------------------|----------------------|---------------------|
| Trimethoprim | 0.034 | 16.000 | 3.000 |
| A | 0.002 | 0.002 | 0.012 |
| B | 0.002 | 0.008 | 0.022 |
| C | 0.001 | 0.001 | 0.002 |
| D | 0.002 | 0.003 | 0.009 |
| E | 0.002 | 0.012 | 0.018 |
| F | 0.001 | 0.003 | 0.009 |
| G | 0.002 | 0.006 | 0.005 |
| H | 0.0003 | 0.0004 | 0.0012 |
| I | 0.0004 | 0.0004 | 0.0004 |
| J | 0.0003 | 0.0002 | 0.0015 |
| K | 0.0006 | 0.0006 | 0.0025 |

The products in accordance with the invention can be used as medicaments, e.g. in the form of pharmaceutical preparations for enteral or parenteral administration. For example, the products in accordance with
5 the invention can be administered perorally, e.g. in the form of tablets, coated tablets, dragées, hard and soft gelatine capsules, solutions, emulsions or suspensions, rectally, e.g. in the form of suppositories, or parentally, e.g. in the form of injection solutions.

The production of the pharmaceutical preparations can be affected in a
10 manner which will be familiar to any person skilled in the art by bringing the substances in accordance with the invention, optionally in combination with other therapeutically valuable substances, into a galenical administration form together with suitable, non-toxic, inert therapeutically compatible solid or liquid carrier materials and, if desired, the usual
15 pharmaceutical adjuvants.

Both inorganic and organic carrier materials are suitable as such carrier materials. Thus, for example, lactose, corn starch or derivatives thereof, talc, stearic acid or its salts can be used as carriers for tablets, coated tablets, dragées and hard gelatine capsules. Suitable carriers for soft
20 gelatine capsules are, for example, vegetable oils, waxes, fats and semi-solid

and liquid polyols (depending on the nature of the active ingredient no carriers are, however, required in the case of soft gelatine capsules).

Suitable carrier materials for the production of solutions and syrups are, for example, water, polyols, sucrose, invert sugar and glucose. Suitable carrier materials for injection solutions are, for example, water, alcohols, polyols, glycerol and vegetable oils. Suitable carrier materials for suppositories are, for example, natural or hardened oils, waxes, fats and semi-liquid or liquid polyols.

The usual preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents and antioxidants come into consideration as pharmaceutical adjuvants. For parenteral administration the compounds of formula I and, respectively, their salts are preferably provided as lyophilizates or dry powders for dilution with usual carriers such as water or isotonic saline.

As mentioned earlier, the compounds of formula I and their salts have antibacterial activity. They inhibit bacterial dihydrofolate reductase and potentiate the antibacterial activity of sulphonamides, such as e.g. sulfisoxazole, sulfadimethoxine, sulfamethoxazole, 4-sulphanilamido-5,6-dimethoxypyrimidine, 2-sulphanilamido-4,5-dimethylpyrimidine or sulfaquinoxaline, sulfadiazine, sulfamonomethoxine, 2-sulphanilamido-4,5-dimethylisoxazole and other inhibitors of enzymes which are involved in folic acid biosynthesis, such as e.g. pteridine derivatives.

Oral, rectal and parenteral administration come into consideration in human medicine for such combinations of one or more compounds I in accordance with the invention with sulphonamides. The ratio of compound I to sulphonamide can vary within a broad range; it amounts to e.g. between 1:40 (parts by weight) and 1:1 (parts by weight); preferred ratios are 1:10 to 1:2.

Thus, e.g., a tablet can contain 80 mg of a compound I in accordance with the invention and 400 mg of sulfamethoxazole, a paediatric tablet can contain 20 mg of a compound I in accordance with the invention and 100 mg of sulfamethoxazole; syrup per 5 ml can contain 40 mg of compound I and 200 mg of sulfamethoxazole.


A daily dosage of about 0.2 g to about 2 g of a compound of formula I in accordance with the invention comes into consideration for adults.

The compounds of formula I are characterized by a high antibacterial activity and a pronounced synergetic affect in combination with sulphon-
5 amides and are well tolerated.

The following Examples illustrate the invention in more detail.

Example 1

1.1. Preparation of (E)-(RS)-3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-(1-phenyl-1H-phthalazin-2-yl)-propenone



10

A solution 1.25 g of 5-(3-iodo-4,5-dimethoxy-benzyl)-pyrimidine-2,4-diamine and 45 mg of bis-(triphenylphosphine)-palladium(II) dichloride in 18 ml of N,N-dimethylformamide is heated to 120°C and treated dropwise at this temperature with a solution of 850 mg of (RS)-1-(1-phenyl-1H-phthalazin-2-yl)-propenone in 7 ml of N,N-dimethylformamide and 4.5 ml of triethyl-
15 amine. After a reaction period of 30 min. at 120°C the dark mixture is concentrated on a rotary evaporator and the residue is chromatographed on 130 g of silica gel (eluent: methylene chloride/methanol/25% ammonia 95:5:0.5 v/v). The pure fractions are combined, concentrated and re-
20 precipitated from ethyl acetate/hexane. 316 mg (19%) of (E)-(RS)-3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-(1-phenyl-1H-phthalazin-2-yl)-propenone were isolated as a beige product, m.p. 130°C.

The following compounds were prepared in analogy to Example 1.1.:

1.2. (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-
25 phenyl]-1-(1-pyridin-2-yl-1H-phthalazin-2-yl)-propenone, m.p. 146°C.

1.3. (E)-(RS)-1-(1-Butyl-1H-phthalazin-2-yl)-3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-propenone, m.p. 110°C, dec.

- 1.4. (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-(1-furan-2-yl-1H-phthalazin-2-yl)-propenone, m.p. 140°C.
- 1.5. (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-(1-thiazol-2-yl-1H-phthalazin-2-yl)-propenone, m.p. 145°C.
- 5 1.6. (E)-(RS)-2-(2-{3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-acryloyl}-1,2-dihydro-phthalazin-1-yl)-N,N-dimethyl-benzene-sulphonamide, m.p. 160°C.
- 1.7. (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-(2-dimethylaminomethyl-phenyl)-1H-phthalazin-2-yl]-
10 propenone, m.p. 106°C, dec.
- 1.8. (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-(5-methyl-pyridin-2-yl)-1H-phthalazin-2-yl]-propenone, MS (ISP): 536 (M+H)⁺.
- 1.9. (E)-(RS)-2-(2-{3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-acryloyl}-1,2-dihydro-phthalazin-1-yl)-cyclopentanone (mixture of
15 diastereomers), MS (ISP): 527 (M+H)⁺.
- 1.10. (E)-(RS)-2-(2-{3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-acryloyl}-1,2-dihydro-phthalazin-1-yl)-cyclohexanone (mixture of diastereomers), MS (ISP): 541 (M+H)⁺.
- 20 1.11. (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-(2-oxo-propyl)-1H-phthalazin-2-yl]-propenone, MS (ISP): 501 (M+H)⁺.
- 1.12. Methyl (E)-(RS)-2-(2-{3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-acryloyl}-1,2-dihydro-phthalazin-1-yl)-2-methyl-
25 propionate, MS (ISP): 545 (M+H)⁺.
- 1.13. (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-(2-oxo-2-phenyl-ethyl)-1H-phthalazin-2-yl]-propenone, MS (ISP): 563 (M+H)⁺.
- 1.14. (E)-(RS)-3-(2-{3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-acryloyl}-1,2-dihydro-phthalazin-1-yl)-tetrahydro-pyran-2-one
30 (mixture of diastereomers), MS (ISP): 543 (M+H)⁺.

- 1.15. (E)-(RS)-3-[5-(2,4-dAmino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-(1-methyl-2-oxo-2-phenyl-ethyl)-1H-phthalazin-2-yl]-propenone (mixture of diastereomers), MS (ISP): 577 (M+H)⁺.
- 1.16. (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-(2-furan-2-yl-2-oxo-ethyl)-1H-phthalazin-2-yl]-propenone , MS (ISP): 553 (M+H)⁺.
- 1.17.(E)-(RS)- 3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-(1-methylsulfanylmethyl-1H-phthalazin-2-yl)-propenone, m.p. = 205°.
- 10 1.18.(E)-(RS)- 1-[1-(4-tert-Butyl-phenyl)-1H-phthalazin-2-yl]-3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-propenone, m.p. = 123°.
- 1.19.(E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-(1-p-tolyl-1H-phthalazin-2-yl)-propenone, m.p. = 145°.
- 15 1.20. (E)-(RS)- 3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-(4-ethyl-phenyl)-1H-phthalazin-2-yl]-propenone, m.p. = 107°.
- 1.21. (E)-(RS)- 3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-(4-trifluoromethoxy-phenyl)-1H-phthalazin-2-yl]-propenone, m.p. = 127°.
- 20 1.22.(E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-(3,4-dimethyl-phenyl)-1H-phthalazin-2-yl]-propenone, m.p. =139°.
- 1.23.(E)-(RS)- 1-(1-tert-Butyl-1H-phthalazin-2-yl)-3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-propenone, m.p. =90°.
- 25 1.24. (E)-(RS)- 3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-(5,6-dihydro-4H-pyran-2-yl)-1H-phthalazin-2-yl]-propenone, MS (ISP): 527.3 (M+H)⁺.
- 1.25.(E)-(RS)- 3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-(2,4,6-trimethyl-phenyl)-1H-phthalazin-2-yl]-propenone, MS (ISP): 563.5 (M+H)⁺.
- 30

- 1.26.(E)-R-(-)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-(1-phenyl-1H-phthalazin-2-yl)-propenone; $[\alpha]_D = -661^\circ$ (c=1; methanol).
- 1.27.(E)-S-(+)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-(1-phenyl-1H-phthalazin-2-yl)-propenone; $[\alpha]_D = +664^\circ$ (c=1; methanol).
- 1.28.(E)-S-(-)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-(1-furan-2-yl-1H-phthalazin-2-yl)-propenone; $[\alpha]_D = -543^\circ$ (c=1; methanol).
- 1.29.(E)-R-(+)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-(1-furan-2-yl-1H-phthalazin-2-yl)-propenone; $[\alpha]_D = +580^\circ$ (c=1; methanol).
- 1.30.(E)-R-(-)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-(1-propyl-1H-phthalazin-2-yl)-propenone; $[\alpha]_D = -739^\circ$ (c=1; methanol).
- 1.31.(E)-S-(+)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-(1-propyl-1H-phthalazin-2-yl)-propenone; $[\alpha]_D = +790^\circ$ (c=1; methanol).
- 1.32.(E)-R-(-)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-(1-methyl-1H-phthalazin-2-yl)-propenone; $[\alpha]_D = -724^\circ$ (c=1; methanol).
- 1.33.(E)-S-(+)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-(1-methyl-1H-phthalazin-2-yl)-propenone; $[\alpha]_D = +689^\circ$ (c=1; methanol).
- 1.34 (E)-(RS)-1-(1-Biphenyl-4-yl-1H-phthalazin-2-yl)-3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-propenone, m.p. 147°C (acetonitrile). MS (ISP): 597.3 (M+H)⁺.
- 1.35 Mixture of (E)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[(RS)- und -(SR)-1-[4-[(RS)-1-ethoxy-ethoxy]-phenyl]-1H-phthalazin-2-yl]-propenone, m.p. 130°C (ethanol). MS (ISP): 609.3 (M+H)⁺.

- 1.36 (E)-1-[(RS)-1-Bicyclo[2.2.1]hept-2endo- and/or 2exo-yl-1H-phthalazin-2-yl]-3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-propenone, m.p. 113-116°C (methanol). MS (ISP): 539.4 (M+H)⁺.
- 1.37 (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-(6-methyl-pyridin-2-yl)-1H-phthalazin-2-yl]-propenone, m.p. 134-138°C (ethanol). MS (ISP): 536.3 (M+H)⁺.
- 1.38 (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-(4-dimethylamino-phenyl)-1H-phthalazin-2-yl]-propenone, m.p. 270-275°C (acetonitrile/methanol). MS (ISP): 564.4 (M+H)⁺.
- 10 1.39 (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-[4-(2-ethoxy-ethoxy)-phenyl]-1H-phthalazin-2-yl]-propenone, m.p. 111-115°C (ethanol). MS (ISP): 609.3 (M+H)⁺.
- 1.40 (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-(1-m-tolyl-1H-phthalazin-2-yl)-propenone, m.p. 134-139°C (methanol). MS (ISP): 535.4 (M+H)⁺.
- 15 1.41 (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-(3,5-dimethyl-phenyl)-1H-phthalazin-2-yl]-propenone, m.p. 134-137°C (methanol). MS (ISP): 549.3 (M+H)⁺.
- 1.42 (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-(4-pyrrol-1-yl-phenyl)-1H-phthalazin-2-yl]-propenone, m.p. 137-143°C (ethanol). MS (ISP): 586.4 (M+H)⁺.
- 20 1.43 (E)-(R)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-(6-methyl-pyridin-3-yl)-1H-phthalazin-2-yl]-propenone, m.p. 140-143°C (acetonitrile), $[\alpha]_D = +614^\circ$ (c=1, chloroform). MS (ISP): 536.4 (M+H)⁺.
- 25 1.44 (E)-(S)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-(6-methyl-pyridin-3-yl)-1H-phthalazin-2-yl]-propenone, m.p. 139-142°C (acetonitrile/ethanol), $[\alpha]_D = -626^\circ$ (c=1, chloroform). MS (ISP): 536.4 (M+H)⁺.
- 1.45 (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-(2,3-dihydro-benzo[1,4]dioxin-6-yl)-1H-phthalazin-2-yl]-propenone, m.p. 212-215°C (methanol). MS (ISP): 579.2 (M+H)⁺.
- 30

- 1.46 (E)-(RS)-1-(1-Cyclopropyl-1H-phthalazin-2-yl)-3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-propenone, m.p. 230-236°C (acetonitrile/ethanol). MS (ISP): 485.4 (M+H)⁺.
- 1.47 (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-(4-methylsulfanyl-phenyl)-1H-phthalazin-2-yl]-propenone, m.p. 168-172°C (acetonitrile). MS (ISP): 567.6 (M+H)⁺.
- 1.48 (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-(6-methyl-pyridin-3-yl)-1H-phthalazin-2-yl]-propenone, m.p. 153-156°C (ethanol). MS (ISP): 536.4 (M+H)⁺.
- 10 1.49 (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-(1-[1,3]dithian-2-yl-1H-phthalazin-2-yl)-propenone, m.p. 235-240°C (acetonitrile). MS (ISP): 563.4 (M+H)⁺.
- 1.50 (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-(6-dimethylamino-pyridin-3-yl)-1H-phthalazin-2-yl]-propenone, 15 m.p. 128-132°C (methanol). MS (ISP): 565.4 (M+H)⁺.
- 1.51 (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-(1-pyridin-3-yl-1H-phthalazin-2-yl)-propenone, mp. 138-142°C (methanol), MS (ISP): 522.2 (M+H)⁺.
- 1.52 (E)-(R)-1-(1-Cyclopropyl-1H-phthalazin-2-yl)-3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-propenone, m.p. 125-128°C 20 (methanol), $[\alpha]_D = +845^\circ$ (c=1, chloroform). MS (ISP): 485.3 (M+H)⁺.
- 1.53 (E)-(S)-1-(1-Cyclopropyl-1H-phthalazin-2-yl)-3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-propenone, m.p. 123-130°C (methanol), $[\alpha]_D = -824^\circ$ (c=0.1, chloroform). MS (ISP): 485.3 (M+H)⁺.
- 25 1.54 (E)-(R)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-(4-methylsulfanyl-phenyl)-1H-phthalazin-2-yl]-propenone, m.p. 139-143°C (acetonitril), $[\alpha]_D = +581^\circ$ (c=1, chloroform). MS (ISP): 567.3 (M+H)⁺.
- 1.55 (E)-(S)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-(4-methylsulfanyl-phenyl)-1H-phthalazin-2-yl]-propenone, m.p. 137-30 142°C (acetonitrile), $[\alpha]_D = -590^\circ$ (c=1, chloroform). MS (ISP): 567.4 (M+H)⁺.


- 1.56 (E)-(RS)-1-(1-Cyclobutyl-1H-phthalazin-2-yl)-3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-propenone, m.p. 122-129°C (methanol), MS (ISP): 499.3 (M+H)⁺.
- 1.57 (E)-(RS)-1-(1-Cyclopentyl-1H-phthalazin-2-yl)-3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-propenone, m.p. 118-123°C (methanol). MS (ISP): 513.4 (M+H)⁺.
- 1.58 (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-(4-trifluoromethyl-phenyl)-1H-phthalazin-2-yl]-propenone, m.p. 189-192°C (methanol). MS (ISP): 589.3 (M+H)⁺.
- 10 1.59 (E)-(RS)-1-[1-(5-Chloro-pyridin-2-yl)-1H-phthalazin-2-yl]-3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-propenone, m.p. 133°C (methanol). MS (ISP): 556.2 (M+H)⁺.
- 1.60 (E)-(RS)-1-(1-Cyclohexyl-1H-phthalazin-2-yl)-3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-propenone, m.p. 120°C (methanol). MS (ISP): 527.3 (M+H)⁺.
- 15 1.61 (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-(4-methoxy-phenyl)-1H-phthalazin-2-yl]-propenone, m.p. 199-201°C (methanol). MS (ISP): 551.2 (M+H)⁺.
- 1.62 (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-(3,4-dimethoxy-phenyl)-1H-phthalazin-2-yl]-propenone, m.p. 155°C (methanol). MS (ISP): 581.3 (M+H)⁺.
- 20 1.63 (E)-(RS)-1-(1-Benzo[1,3]dioxol-5-yl-1H-phthalazin-2-yl)-3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-propenone, m.p. 131-136°C (methanol). MS (ISP): 565.3 (M+H)⁺.
- 25 1.64 (E)-(RS)-4-[2-[3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-acryloyl]-1,2-dihydro-phthalazin-1-yl]-benzonitril, m.p. 138-146°C (methanol). MS (ISP): 546.2 (M+H)⁺.
- 1.65 (E)-(RS)-4-[2-[3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-acryloyl]-1,2-dihydro-phthalazin-1-yl]-benzoic acid tert-butyl ester, m.p. 165-169°C (methanol). MS (ISP): 621.5 (M+H)⁺.
- 30

- 1.66 (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-(1-thiophen-2-yl-1H-phthalazin-2-yl)-propenone, m.p. 150-155°C (ethanol). MS (ISP): 527.3 (M+H)⁺.
- 1.67 (E)-(RS)-1-[1-(5-Butyl-thiophen-2-yl)-1H-phthalazin-2-yl]-3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-propenone, m.p. 107-111°C (methanol). MS (ISP): 583.3 (M+H)⁺.
- 1.68 mixture of (E)-3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[(RS)- and -[(SR)-1-[4-[(RS)-1-hydroxy-ethyl]-phenyl]-1H-phthalazin-2-yl]-propenone, m.p. 225-230°C (methanol). MS (ISP): 565.4 (M+H)⁺.
- 1.69 (E)-(RS)-1-(1-Benzenesulfonylmethyl-1H-phthalazin-2-yl)-3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-propenone, m.p. 128-133°C (methanol). MS (ISP): 599.2 (M+H)⁺.
- 1.70 (E)-(RS)-4-[2-[3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-acryloyl]-1,2-dihydro-phthalazin-1-yl]-N,N-dimethyl-benzenesulfonamid, m.p. 133-135°C (methylenchloride/methanol). MS (ISP): 628.3 (M+H)⁺.
- 1.71 (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-(4-methoxymethyl-phenyl)-1H-phthalazin-2-yl]-propenone, m.p. 165-167°C (methanol). MS (ISP): 565.4 (M+H)⁺.
- 1.72 (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-[4-[(diisopropylamino)-methyl]-phenyl]-1H-phthalazin-2-yl]-propenone, m.p. 139-144°C (methanol). MS (ISP): 634.4 (M+H)⁺.
- 1.73 (E)-(RS)-1-[1-(4-Chloro-phenyl)-1H-phthalazin-2-yl]-3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-propenone, m.p. 158-160°C (acetonitrile). MS (ISP): 555.2 (M+H)⁺.
- 1.74 (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-(6-methoxy-pyridin-3-yl)-1H-phthalazin-2-yl]-propenone, m.p. 124-130°C (methanol). MS (ISP): 552.3 (M+H)⁺.
- 1.75 (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-1H-phthalazin-2-yl]-propenone, m.p. 145°C. MS (ISP): 633.4 (M+H)⁺.

- 1.76 (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-(4-morpholin-4-ylmethyl-phenyl)-1H-phthalazin-2-yl]-propenone, m.p. 85-88°C (ethanol). MS (ISP): 620.4 (M+H)⁺.
- 1.77 (E)-(RS)-1-(1-Adamantan-2-yl-1H-phthalazin-2-yl)-3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-propenone, m.p. 185-188°C (methylenchloride/methanol). MS (ISP): 579.3 (M+H)⁺.
- 1.78 (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-[6-(1-hydroxy-1-methyl-ethyl)-pyridin-3-yl]-1H-phthalazin-2-yl]-propenone, m.p. 147-152°C (ethanol). MS (ISP): 580.2 (M+H)⁺.
- 10 1.79 (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-(6-morpholin-4-yl-pyridin-3-yl)-1H-phthalazin-2-yl]-propenone, m.p. 142-148°C (ethanol). MS (ISP): 607.2 (M+H)⁺.
- 1.80 (E)-(RS)-5-(2-[3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-acryloyl]-1,2-dihydro-phthalazin-1-yl)-pyridin-2-carbonic acid tert-butylamide, m.p. 140-148°C (methylenchlorid/methanol). MS (ISP): 621.2 (M+H)⁺.
- 15

Example 2

2.1. Preparation of (E)-(RS)-3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-(4-fluoro-phenyl)-1H-phthalazin-2-yl]-propenone



20

- A solution of 0.819 g of 5-(3-iodo-4,5-dimethoxy-benzyl)-pyrimidin-2,4-diamine and 0.89 g of (RS)-1-[1-(4-fluoro-phenyl)-1H-phthalazin-2-yl]-propenone in 15 ml of N,N-dimethylacetamide and 1.9 ml of triethylamine is treated with
- 25 22 mg of palladium-(II) acetate and 127 mg of tri-o-tolylphosphine and heated to 120°C for 2.5 hrs. Subsequently, the hot orange solution is poured

into 50 ml of aqueous saturated sodium hydrogen carbonate solution and stirred at room temperature for 15 min. The resulting precipitate is filtered off under suction dried and chromatographed over silica gel with dichloromethane/methanol 95:5. The pure fractions are combined, concentrated and
5 crystallized from dichloromethane/tert.butyl methyl ether. 603 mg (53%) of E)-(RS)-3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-(4-fluoro-phenyl)-1H-phthalazin-2-yl]-propenone are isolated as a colourless product, m.p. 114°C, dec.

The following compounds were prepared in analogy to Example 2.1.:

10 2.2. (E)-(RS)- 3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-(2,4-difluoro-phenyl)-1H-phthalazin-2-yl]-propenone, m.p. 121°C, dec.

2.3. (E)-(RS)- 3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-(1-tridecafluorohexyl-1H-phthalazin-2-yl)-propenone, m.p. 143°C,
15 dec.

2.4. (E)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-(1H-phthalazin-2-yl)-propenone, m.p. 164°C, dec.

2.5. (E)-(RS)-1-(1-Phenylsulphinylmethyl-1H-phthalazin-2-yl)-3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-propenone, m.p.
20 135-138°C.

2.6. (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-(4-hydroxymethyl-phenyl)-1H-phthalazin-2-yl]-propenone, m.p. 265°C.

2.7. (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-(4-hydroxy-phenyl)-1H-phthalazin-2-yl]-propenone, MS (ISP):
25 537.3 (M+H)⁺

2.8. (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-(2-hydroxymethyl-phenyl)-1H-phthalazin-2-yl]-propenone.
M.p. 259°C


30 2.9. (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-(3-hydroxymethyl-phenyl)-1H-phthalazin-2-yl]-propenone.
M.p. 178-79°C.

- 2.10. (E)-(RS)-3-{ 5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl}-1-{1-(3-hydroxy-phenyl)-1H-phthalazin-2-yl}-propenone. M.p. 169-171°C
- 2.11. (E)-(RS)-3-{5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl}-1-(1-methyl-1H-phthalazin-2-yl)-propenone. M.p. 226°C
- 2.12. (E)-(RS)-3-{5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl}-1-{1-(4-(2-hydroxyethyl)-phenyl)-1H-phthalazin-2-yl}-propenone. M.p. 260°C.
- 2.13. (E)-(RS)-3-{5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl}-1-(1-ethyl-1H-phthalazin-2-yl)-propenone. MS (ISP): 473.4 (M+H)⁺
- 2.14. (E)-(RS)-3-{5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl}-1-{1-(4-carbamoyloxymethyl-phenyl)-1H-phthalazin-2-yl}-propenone. MS (ISP): 594.4 (M+H)⁺
- 2.15. (E)-(RS)-3-{5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl}-1-(1-propyl-1H-phthalazin-2-yl)-propenone. MS (ISP): 487.4 (M+H)⁺
- 2.16. (E)-(RS)-3-{5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl}-1-(1-prop-2-yl-1H-phthalazin-2-yl)-propenone. MS (ISP): 487.4 (M+H)⁺
- 2.17. (E)-(RS)-3-{5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl}-1-{1-(3-methyl-butyl)-1H-phthalazin-2-yl}-propenone. MS (ISP): 515.5 (M+H)⁺
- 2.18. (E)-(RS)-3-{5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl}-1-(3-hydroxy-prop-1-yl-1H-phthalazin-2-yl)-propenone. MS (ISP): 503.3 (M+H)⁺
- 2.19. (E)-(RS)-Morpholine-4-carboxylic acid 4-(2-{3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-acryloyl}-1,2-dihydro-phthalazin-1-yl)-butyl ester. MS (ISP): 630.4 (M+H)⁺
- 2.20. (E)-(RS)-3-{5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl}-1-{(4-hydroxy-but-1-yl)-1H-phthalazin-2-yl}-propenone. MS (ISP): 517.3 (M+H)⁺

- 2.21.(E)-(RS)-Carbamic acid 4-(2-{3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-acryloyl}-1,2-dihydro-phthalazin-1-yl)-butyl ester.
MS(ISP): 560.3 (M+H)⁺
- 2.22.(E)-(RS)-Carbamic acid 4-(2-{3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-acryloyl}-1,2-dihydro-phthalazin-1-yl)-propyl ester.
5 MS (ISP): 546.3 (M+H)⁺
- 2.23.(E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-(2-[1,3]dioxolan-2-yl-ethyl)-1H-phthalazin-2-yl]-propenone. MS
(ISP): 545.3 (M+H)⁺
- 10 2.24.(E)-(RS)-1-Cyclohexylmethyl-1H-phthalazin-2-yl)-3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]propenone. MS (ISP): 541.4 (M+H)⁺

Example 3

- 15 3.1. Preparation of (E)-(RS)-3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-3-methoxy-2-methoxymethoxy-phenyl]-1-(1-phenyl-1H-phthalazin-2-yl)-propenone



- 20 A solution of 806 mg of 5-(3-iodo-5-methoxy-4-methoxymethoxy-benzyl)-pyrimidine-2,4-diamine and 28 mg of bis-(triphenylphosphine)-palladium-(II) dichloride in 11 ml of N,N-dimethylformamide is heated to 120°C and treated dropwise at this temperature with a solution of 524 mg of (RS)-1-(1-phenyl-1H-phthalazin-2-yl)-propenone in 4 ml of N,N-dimethylformamide
25 and 2.8 ml of triethylamine. After a reaction period of 3 hrs. at 120°C the dark mixture is concentrated and the residue is chromatographed on 330 g

of silica gel (eluent: methylene chloride/methanol 1:1 v/v). The pure fractions are combined. After isolation by concentration there are obtained 500 mg of (E)-(RS)-3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-3-methoxy-2-methoxymethoxy-phenyl]-1-(1-phenyl-1H-phthalazin-2-yl)-propenone as a yellowish foam. MS (ISP): 551 (M+H)⁺.


The following compounds were prepared in analogy to example 3:

3.2. (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-3-methoxy-2-methoxymethoxy-phenyl]-1-(1-furan-2-yl-1H-phthalazin-2-yl)-propenone, MS (ISP): 541 (M+H)⁺.

3.3. (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-3-methoxy-2-methoxymethoxy-phenyl]-1-[1-(4-hydroxymethyl-phenyl)-1H-phthalazin-2-yl]-propenone, MS (ISP): 581 (M+H)⁺.

Example 4

Preparation of (E)-(RS)-3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1[2-(2,2-dimethyl-[1,3]-dioxolan-4-yl)-ethyl]-1H-phthalazin-2-yl]-propenone




A solution of 1.3 g of 5-(3-iodo-4,5-dimethoxy-benzyl)-pyrimidin-2,4-diamine, 100 mg of bis-(triphenylphosphine)-palladium-(II) dichloride, 1.1 g of sodium bicarbonate, 4.7 ml of triethylamine and 1.2 g of (E)-(RS)-1-[1[2-(2,2-dimethyl-[1,3]-dioxolan-4-yl)-ethyl]-1H-phthalazin-2-yl]-propenone in 25 ml of dimethylformamide is heated to 120°C. After 5 hrs. the pale yellow mixture is concentrated on a rotary evaporator and the residue is chromatographed on silica gel (eluent: CH₂Cl₂/MeOH/NH₄OH: 95/5/0.5). The pure fractions are combined, concentrated and crystallized from CH₂Cl₂. 720 mg of (E)-

(RS)-3-{ 5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl}-1-[2-(2,2-dimethyl-[1,3]-dioxolan-4-yl)-ethyl]-1H-phthalazin-2-yl]-propenone are isolated as a beige product. MS (ISP): 573.5 (M+H)⁺

Example 5


- 5 Preparation of (E)-(RS)-3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-3-methoxy-2-(2-morpholin-4-yl-ethoxy)-phenyl]-1-(1-phenyl-1H-phthalazin-2-yl)-propenone



- A solution of 120 mg of 5-{3-iodo-5-methoxy-4-(2-morpholin-4-yl-ethoxy)-benzyl}-pyrimidine-2,4-diamine and 28 mg of bis-(triphenylphosphine)-palladium-(II) dichloride in 1.5 ml of N,N-dimethylformamide is heated to 120°C and treated dropwise at this temperature with a solution of 76 mg of (RS)-1-(1-phenyl-1H-phthalazin-2-yl)-propenone in 0.75 ml of N,N-dimethylformamide and 0.75 ml of triethylamine. After 2.5 hrs. at 120°C the dark reaction mixture is concentrated and the residue is chromatographed on 50 g of silica gel (eluent, methylene chloride/methanol 1:1 v/v). The pure fractions are combined. 54 mg of (E)-(RS)-3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-3-methoxy-2-(2-morpholin-4-yl-ethoxy)-phenyl]-1-(1-phenyl-1H-phthalazin-2-yl)-propenone are isolated as a yellowish foam. MS (ISP): 620(M+H)⁺.

Example 6


Preparation of methyl (E)-(RS)-{4-(2,4-diamino-pyrimidin-5-ylmethyl)-2-methoxy-6-[3-oxo-3-(1-phenyl-1-H-phthalazin-2-yl)-propenyl]-phenoxy}-acetate



A solution of 380 mg of methyl {4-(2,4-diamino-pyrimidin-5-ylmethyl)-2-iodo-6-methoxy-phenoxy}-acetate and 96 mg of bis-(triphenylphosphine)-palladium-(II)dichloride in 5 ml of N,N-dimethylformamide is heated to 120°C and treated dropwise at this temperature with a solution of 250 mg of (RS)-1-(1-phenyl-1H-phthalazin-2-yl)-propenone in 2.5 ml of N,N-dimethylformamide and 2.5 ml of triethylamine. After 2.5 hrs. at 120°C the dark reaction mixture is concentrated and the residue is chromatographed on 100 g of silica gel (eluent: methylene chloride/methanol 1:1 v/v). The pure fractions are combined. 268 mg of methyl (E)-(RS)-{4-(2,4-diamino-pyrimidin-5-ylmethyl)-2-methoxy-6-{3-oxo-3-(1-phenyl-1-H-phthalazin-2-yl)-propenyl}-phenoxy}-acetate are isolated as a yellowish foam. MS (ISP): 579 (M+H)⁺.

Example 7

Preparation of (E)-(RS)-2-(2-{3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-acryloyl}-1,2-dihydro-phthalazin-1-yl)-2-methyl-propionic acid




To the solution of 50 mg of methyl (E)-(RS)-2-(2-{3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-acryloyl}-1,2-dihydro-phthalazin-1-yl)-2-methyl-propionate (Example 1.12) in 5 ml of methanol are added 3 drops of 2N sodium hydroxide solution and the mixture is held at reflux for 45 min. Subsequently, the mixture is concentrated, the residue is treated with ice-

water and neutralized with 2N hydrochloric acid. The insoluble material is recrystallized from methylene/methanol. 41 mg of (E)-(RS)-2-(2-{3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-acryloyl}-1,2-dihydro-phthalazin-1-yl)-2-methyl-propionic acid are isolated as a colourless solid.

5 M.p = 245°C, dec.

Example 8

8.1. Preparation of (E)-(RS)-3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-2-hydroxy-3-methoxy-phenyl]-1-(1-phenyl-1H-phthalazin-2-yl)-propenone



10

290 mg of (E)-(RS)-3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-3-methoxy-2-methoxymethoxy-phenyl]-1-(1-phenyl-1H-phthalazin-2-yl)-propenone;

Example 3.1. are dissolved in 10 ml of methanol and treated with 10 drops of conc. hydrochloric acid. After one hour at 70°C the mixture is concentrated
15 and the residue is chromatographed on 250 g of silica gel (eluent: methylene chloride/methanol). 228 mg of (E)-(RS)-3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-2-hydroxy-3-methoxy-phenyl]-1-(1-phenyl-1H-phthalazin-2-yl)-propenone are isolated as an orange, hygroscopic solid. MS (ISP): (M+H)⁺

The following compounds were prepared in analogy [to] 8.1.:


20 8.2. (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2-hydroxy-3-methoxy-phenyl]-1-(1-furan-2-yl-1H-phthalazin-2-yl)-propenone, m.p. 158°C, dec.

8.3. (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2-hydroxy-3-methoxy-phenyl]-1-[1-(4-hydroxymethyl-phenyl)-1H-phthalazin-2-yl]-propenone, m.p. > 250°C.

25

Example 9

9.1. Preparation of 2-amino-propionic acid 4-(2-{3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-acryloyl}-1,2-dihydro-phthalazin-1-yl)-benzyl ester




- 5 A solution of 130 mg of 2-tert-butoxycarbonylamino-propionic acid 4-(2-{3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-acryloyl}-1,2-dihydro-phthalazin-1-yl)-benzyl ester in 20 ml of trifluoroethanol is treated with 18 μ l of methanesulphonic acid at room temperature over one hour. The reaction solution is concentrated, the residue is taken up in ethyl acetate and filtered. The crystals are dissolved in 5 ml of water and treated with 20 ml of pH 7 buffer. The suspension obtained is suction filtered. There are obtained 65 mg of 2-amino-propionic acid 4-(2-{3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-acryloyl}-1,2-dihydro-phthalazin-1-yl)-benzyl ester, MS (ISP): 622.3 (M+H)⁺
- 10
- 15 The educt used in Example 9.1. is prepared as follows:
- a) A solution of 275 mg of (E)-(RS)-3-{ 5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl}-1-{1-(4-hydroxymethyl-phenyl)-1H-phthalazin-2-yl}-propenone in 10 ml of dimethylformamide is treated at room temperature with 105 mg of BOC-L-alanine, 95 mg of N-(3-dimethylaminopropyl-N'-ethylcarbodiimide hydrochloride and 30 mg of 4-dimethyl aminopyridine. After one hour the reaction solution is concentrated and the residue is chromatographed on silica gel (eluent: dichloromethane/ ethanol 9/1). 220 mg (61%) of 2-tert-butoxycarbonylamino-propionic acid-4-(2-{3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-acryloyl}-1,2-dihydro-phthalazin-1-yl)-benzyl ester are obtained as a pale yellow solid, MS (ISP) 722.5 (M+H)⁺
- 20
- 25

9.2. 2-Amino-5-guanidino-pentanoic acid 4-(2-[3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-acryloyl]-1,2-dihydro-phthalazin-1-yl)-benzyl ester is prepared in analogy to Example 9.1. MS (ISP): 707.6 (M+H)⁺

The educt used in Example 9.2 (old 1.3.2.) is prepared in analogy to Example 9.1.a) from a 1:1 mixture of (S)-5-(N,N'-bis-tert-butoxycarbonyl-guanidino)-2-tert-butoxycarbonylamino-pentanoic acid (E)-(R)-and -(S)-4-[2-[3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-acryloyl]-1,2-dihydro-phthalazin-1-yl]-benzyl ester. MS (ISP): 1007.9 (M+H)⁺

Example 10

10.1. Preparation of sulphuric acid (E)-(RS)-mono-[4-[2-[3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-acryloyl]-1,2-dihydro-phthalazin-1-yl]-benzyl ester] Na salt (1:1)




A solution 200 mg of (E)-(RS)-3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-(4-hydroxymethyl-phenyl)-1H-phthalazin-2-yl]-propenone in 5 ml of dimethylformamide is treated at room temperature with 67 mg of sulphur trioxide-dimethylformamide complex. After 1 hour 73 mg of sodium bicarbonate and 5 ml of water are added. The solution is stirred for a further hour, thereafter the solution is concentrated, the residue is taken up in 40 ml of methanol/dichloromethane and filtered. The mother liquor is concentrated and the residue is crystallized from methanol. There are obtained 90 mg of sulphuric acid (E)-(RS)-mono-[4-[2-[3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-acryloyl]-1,2-dihydro-phthalazin-1-yl]-benzyl ester] Na salt (1:1), MS (ISP): 631.3 (M+H)⁺

10.2. Sulphuric acid (E)-(RS)-mono-[4-[2-[3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-acryloyl]-1,2-dihydro-phthalazin-1-yl]-butyl ester] Na salt (1:1), MS (ISP): 597.3 (M+H)⁺, is prepared in a analogous manner to Example 10.1.

Example 11


Preparation of (E)-(RS)-3-{ 5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl}-1-{1-(4-thiocyanato-butyl)-1H-phthalazin-2-yl}-propenone



- 5 A solution of 206 mg of (E)-(RS)-3-{ 5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl}-1-{(4-hydroxy-but-1-yl)-1H-phthalazin-2-yl}-propenone in 2 ml of pyridine is treated with 37 μ l of mesyl chloride at -20°C . After one hour the solution is concentrated and the residue, dissolved in 10 ml of dimethylformamide, is treated with 233 mg of potassium rhodanide at 80°C
- 10 for 24 hrs. The reaction solution is concentrated and the residue is chromatographed on silica gel (eluent: $\text{CH}_2\text{Cl}_2/\text{MeOH}/\text{NH}_4\text{OH}$: 95/5/0.5). The pure fractions are combined, concentrated and crystallized from methanol. 124 mg of (E)-(RS)-3-{ 5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl}-1-{1-(4-thiocyanato-butyl)-1H-phthalazin-2-yl}-propenone
- 15 are obtained as white crystals. MS (ISP): 558.3 (M+H) $^{+}$

Example 12

Preparation of (E)-(RS)-3-{ 5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl}-acryloyl-1,2-dihydrophthalazin-1-yl-propionaldehyde




- 20 A solution of 764 mg of (E)-(RS)-3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-(2-[1,3]dioxolan-2-yl-ethyl)-1H-phthalazin-2-yl]-propenone in 20 ml of acetone and 3 ml of water is treated with 3 ml of 2N hydrochloric acid over two days. The pH is adjusted to pH 7-8 using sodium bicarbonate solution and the aqueous phase is extracted three times with

dichloromethane/methanol (9:1). The organic phase is back-washed with sodium chloride solution, dried over magnesium sulphate, filtered and the filtrate is concentrated. The residue is chromatographed on silica gel (eluent: CH₂Cl₂/MeOH/ NH₄OH: 9/1/1). The pure fractions are combined, concentrated and crystallized from dichloromethane/hexane. The crystals are taken up in 150 ml of dichloromethane, stirred and suction filtered. The mother liquor is concentrated to about 25 ml and diluted with hexane. The crystals obtained are filtered off under suction. 388 mg of not quite pure (E)-(RS)-3-{ 5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl}-acryloyl-1,2-dihydrophthalazin-1-yl-propionaldehyde are obtained.

Example 13

13.1. Preparation of a mixture of (E) and (Z)-(RS)-5[2-[(E)-3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-acryloyl]-1,2-dihydrophthalazin-1-yl]-pent-2-enenitrile.



15

A suspension of 160 mg of (E)-(RS)-3-{ 5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl}-acryloyl-1,2-dihydrophthalazin-1-yl-propionaldehyde in 30 ml of tetrahydrofuran and 10 ml of dichloromethane is treated with 438 mg of cyanomethylene-triphenylphosphorane. After 12 hrs. the solution is concentrated and the residue is chromatographed on silica gel (eluent: CH₂Cl₂/MeOH/ NH₄OH: 95/5/0.5). The pure fractions are combined, concentrated and cystallized from CH₂Cl₂/MeOH. There are obtained 150 mg of white crystals. MS (ISP): 524.4 (M+H)⁺


The following compounds were prepared analogously to Example 13.1:

13.2. Allyl (E)-(RS)-5[2-[(E)-3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-acryloyl]-1,2-dihydrophthalazin-1-yl]-pent-2-enoate.
MS-(ISP): 583.4 (M+H)⁺

13.3.(EE)-(RS)-3-[3-(2-[3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-acryloyl]-1,2-dihydrophthalazin-1-yl]-propylidene]-1-hydroxy-pyrrolidin-2-one

Example 14

- 5 Preparation of 3-[3-(2-[3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-acryloyl]-1,2-dihydrophthalazin-1-yl]-propylidene]-1-(2-trimethylsilanyl-ethoxy)-pyrrolidin-2-one.




- A mixture of 230 mg of (E)-(RS)-3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-acryloyl-1,2-dihydrophthalazin-1-yl-propionaldehyde, 498 mg of (RS)-[2-oxo-1-(2-trimethylsilanyl-ethoxy)-pyrrolidin-3-yl]-triphenyl-phosphonium, 5 ml of butylene oxide and 5 ml of dichloromethane is heated to 50°C. After 8 hrs. the reaction solution is concentrated and the residue is chromatographed on silica gel (eluent: CH₂Cl₂/MeOH/NH₄OH: 95/5/0.5).
- 15 The pure fractions are combined, concentrated and crystallized from CH₂Cl₂/hexane. There are obtained 222 mg of white crystals, MS (ISP): 684.5 (M+H)⁺.

The educt used in this reaction can be prepared as described in EP-A 0 620 225.

20

Example 15

Preparation of 3-[3-(2-[3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxyphenyl]-acryloyl]-1,2-dihydrophthalazin-1-yl]-propylidene]-1-hydroxy-pyrrolidin-2-one.




A solution of 220 mg of [3-(2-{3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-acryloyl}-1,2-dihydrophthalazin-1-yl)-propylidene]-1-(2-trimethylsilyl-ethoxy)-pyrrolidin-2-one in 2 ml of trifluoroacetic acid is stirred for 20 hrs. and then concentrated. The residue is dissolved in 5 ml of methanol and treated with 57 mg of sodium bicarbonate in 2 ml of water. The reaction solution is concentrated, the residue is dissolved in 5 ml of water and cooled to 0°C. The crystals obtained are filtered off under suction. There are obtained 117 mg of white crystals. MS (ISP): 584.4 (M+H)⁺

10

Example 16

Preparation of (E)-(RS)-3-{ 5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl}-1-[1(3,4-dihydroxy-butyl)-1H-phthalazin-2-yl]-propenone.



A mixture of 250 mg of (E)-(RS)-3-{ 5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl}-1-[1(2-(2,2-dimethyl-[1,3]-dioxolan-4-yl)-ethyl)-1H-phthalazin-2-yl]-propenone in 4 ml of methanol is treated with 0.65 ml of 2N HCl. The pH value is adjusted to 7-8 after one hour and the mixture is concentrated. The residue is taken up in methanol/dichloromethane, dried over magnesium sulphate and filtered. The filtrate is concentrated and the residue is crystallized from methanol. There are obtained 180 mg of substance. MS (ISP): 533.5 (M+H)⁺

20

The educts of formula II which are used can be prepared as follows:

Example 17

17.1. Preparation of 3-iodo-5-methoxy-4-methoxymethoxy-benzaldehyde

14.8 g of potassium carbonate are added a solution of 20 g of 5-iodovanillin in
5 190 ml of N,N-dimethylformamide. The mixture is cooled to about 10°C and
then treated dropwise with 8.1 ml of chloromethyl added thereto within
40 min. The mixture is stirred at room temperature for 30 min., poured on
to about 300 ml of ice-water and extracted 5 times with 150 ml of ethyl acetate
each time. The organic phases are combined dried, concentrated and the
10 residue is recrystallized from diethyl ether. 15.4 g of 3-iodo-5-methyl-4-
methoxymethoxy-benzaldehyde are isolated as a colourless solid.

17.2 Preparation of (E/Z)-2-(3-iodo-5-methoxy-4-methoxymethoxy-benzyl)-3-
phenylamino-acrylonitrile

5.0 g of 3-iodo-5-methyl-4-methoxymethoxy-benzaldehyde and 2.73 g of 3-
15 anilinopropionitrile are dissolved in 90 ml of dimethyl sulphoxide and cooled
to about 10°C. After the portionwise addition of 2.16 g of potassium tert.-
butoxide the mixture is stirred at room temperature for a further 2 hrs., then
treated with 150 ml of water and 100 ml of diethyl ether. The organic phase is
separated, dried and concentrated. After trituration of the residue in diethyl
20 ether 5.65 g of (E/Z)-2-(3-iodo-5-methoxy-4-methoxymethoxy-benzyl)-3-phenyl-
amino-acrylonitrile are obtained as a yellowish solid.

17.3. Preparation of 5-(3-iodo-5-methoxy-4-methoxymethoxy-benzyl)-
pyrimidine-2,4-diamine

2.15 g of sodium methylate are dissolved in 190 ml of ethanol. 3.9 g of
25 guanidine hydrochloride are added there to within 40 min. The mixture is
stirred at room temperature for 1 hr. and subsequently treated portionwise
with 5.0 g of (E/Z)-2-(3-iodo-5-methoxy-4-methoxymethoxy-benzyl)-3-phenyl-
amino-acrylonitrile. The reaction mixture is held at reflux overnight. The
mixture is suction filtered, the insoluble salts are washed with ethanol and
30 the organic phase is dried and concentrated. After recrystallization of the
residue from ethanol there are isolated 3.65 g of 5-(3-iodo-5-methoxy-4-
methoxymethoxy-benzyl)-pyrimidine-2,4-diamine as a colourless solid, m.p.
180°C, dec.

The preparation of the compounds of formula III (educts of Examples 1-16) is effected as described hereinafter or in analogy thereto.

Example 18

18.1. Preparation of (RS)-1-(1-phenyl-1H-phthalazin-2-yl)-propenone

- 5 A solution of 1.11 g of 1-phenyl-1,2-dihydro-phthalazine and 0.67 g of triethylamine in 10 ml of methylene chloride is treated slowly while cooling with ice with a solution of 0.53 g of acryloyl chloride in 10 ml of methylene chloride. Subsequently, the mixture is stirred at room temperature for 20 min., poured on to ice-water and extracted with ethyl acetate. The
10 organic phase is dried, concentrated and chromatographed on 50 g of silica gel; eluent: ethyl acetate/ hexane 3:7 v/v. 1.30 g of (RS)-1-(1-phenyl-1H-phthalazin-2-yl)-propenone are obtained as a colourless oil. MS: 262 (M^+).

The following compounds of formula III were prepared in analogy to Example 18.1.:

- 15 18.2. (RS)-1-(1-(Pyridin-2-yl)-1H-phthalazin-2-yl)-propenone as a yellow resin. MS : 263 (M^+).
- 18.3. (RS)-1-(1-Furan-2-yl-1H-phthalazin-2-yl)-propenone as a yellow oil. MS : 252 (M^+).
- 18.4. (RS)-1-(1-Butyl-1H-phthalazin-2-yl)-propenone as a yellow oil. MS :
20 242 (M^+).
- 18.5. (RS)-1-(1-Thiazol-2-yl-1H-phthalazin-2-yl)-propenone as a yellow solid.
- 18.6. (RS)-2-(2-Acryloyl-1,2-dihydro-phthalazin-1-yl)-N,N-dimethyl-benzenesulphonamide as a greenish, unstable oil. MS (ISP): 370 ($M+H$)⁺.
- 25 18.7. (RS)-1-[1-(2-Dimethylaminomethyl-phenyl)-1H-phthalazin-2-yl]-propenone as a yellowish unstable oil.
- 18.8. (RS)-1-[1-(5-Methyl-pyridin-2-yl)-1H-phthalazin-2-yl]-propenone as a brownish solid.
- 18.9. (RS)-1-[1-(4-Fluoro-phenyl)-1H-phthalazin-2-yl]-propenone as a
30 yellow oil. MS (ISP): 281.1 ($M+H$)⁺.

- 18.10. (RS)-1-[1-(2,4-Difluoro-phenyl)-1H-phthalazin-2-yl]-propenone as a yellowish oil. MS : 298 (M⁺).
- 18.11. (RS)-1-(1-Tridecafluorohexyl-1H-phthalazin-2-yl)-propenone as a yellowish oil. MS (ISP): 505.2 (M+H)⁺.
- 5 18.12. (RS)-1-1-(1-Phenylsulphinylmethyl-1H-phthalazin-2-yl)-propenone as a yellowish oil. MS : 325 (M+H)⁺.
- 18.13. (E)-(RS)-1-{1-Methyl-1H-phthalazin-2-yl}-propenone. MS (EI): 200 (M)
- 18.14. (RS)-1-{1-Ethyl-1H-phthalazin-2-yl}-propenone. MS (EI): 214(M)
- 18.15. (E)-(RS)-1-{1-Propyl-1H-phthalazin-2-yl}-propenone. MS (EI): 228 (M)
- 10 18.16. (E)-(RS)-1-{1-(Isopropyl)-1H-phthalazin-2-yl}-propenone. MS (EI): 228 (M)
- 18.17. (E)-(RS)-1-{1-(3-Methyl-but-1-yl)-1H-phthalazin-2-yl}-propenone. MS (EI): 256 (M)
- 18.18. (E)-(RS)-1-{1[2,2-Dimethyl-[1,3]-dioxolan-4-yl]-ethyl}-1H-phthalazin-2-yl}-propenone. MS (ISP): 315.2 (M+H)⁺
- 15 18.19. (E)-(RS)-1-[1-(2-[1,3]-Dioxolan-2-yl-ethyl)-1H-phthalazin-2-yl]-propenone. MS (ISP): 287.3 (M+H)⁺
- 18.20. (RS)-1-(1-Cyclohexylmethyl-1H-phthalazin-2-yl)-propenone. MS (ISP): 283.4 (M+H)⁺
- 20 18.21. (RS)- (1-Methylsulfanylmethyl-1H-phthalazin-2-yl)-propenone. MS: 247 (M⁺)
- 18.22. (RS)- [1-(4-tert-Butyl-phenyl)-1H-phthalazin-2-yl]-propenenone (yellow oil),
- 18.23. (RS)- (1-p-Tolyl-1H-phthalazin-2-yl)-propenone (yellow oil),
- 25 18.24. (RS)- [1-(4-Ethyl-phenyl)-1H-phthalazin-2-yl]-propenone (yellow oil),
- 18.25. (RS)- [1-(4-Trifluoromethoxy-phenyl)-1H-phthalazin-2-yl]-propenone (yellow oil),

- 18.26. (RS)- [1-(3,4-Dimethyl-phenyl)-1H-phthalazin-2-yl]-propenone (yellow oil),
- 18.27. (RS)- (1-tert-Butyl-1H-phthalazin-2-yl)-propenone MS: 242 (M⁺),
- 18.28. (RS)- [1-(5,6-Dihydro-4H-pyran-2-yl)-1H-phthalazin-2-yl]-propenone
5 MS (ISP): 269.3 (M+H)⁺,
- 18.29. (RS)- [1-(2,4,6-Trimethyl-phenyl)-1H-phthalazin-2-yl]-propenone MS (ISP): 305.3 (M+H)⁺,
- 18.30 (RS)-1-(1-Biphenyl-4-yl-1H-phthalazin-2-yl)-propenone, m.p. 120°C (diisopropylether). MS (ISP): 339.3 (M+H)⁺,
- 10 18.31 (RS)-1-[1-[4-[1-Ethoxy-ethoxy]-phenyl]-1H-phthalazin-2-yl]-propenone, (yellow oil) MS (ISP): 351.3 (M+H)⁺,
- 18.32 (RS)-1-(1-Bicyclo[2.2.1]hept-2endo- and/or 2exo-2-yl-1H-phthalazin-2-yl)-propenone, (yellow oil) MS (ISP): 281.2 (M+H)⁺
- 18.33 (RS)-1-[1-(6-Methyl-pyridin-2-yl)-1H-phthalazin-2-yl]-propenone, m.p.
15 102°C (diisopropylether). MS (ISP): 278.2 (M+H)⁺,
- 18.34 (RS)-1-[1-(4-Dimethylamino-phenyl)-1H-phthalazin-2-yl]-propenone, m.p. 118-122°C (ethyl acetate/hexane). MS (ISP): 306.3 (M+H)⁺.
- 18.35 (RS)-1-[1-[4-(2-Ethoxy-ethoxy)-phenyl]-1H-phthalazin-2-yl]-propenone, b.p. 205°C/0.06 mbar MS (ISP): 351.3 (M+H)⁺.
- 20 18.36 (RS)-1-(1-m-Tolyl-1H-phthalazin-2-yl)-propenone, b.p. 170°C/0.1 mbar MS (EI): 276 (M).
- 18.37 (RS)-1-[1-(3,5-Dimethyl-phenyl)-1H-phthalazin-2-yl]-propenone m.p. 110°C (hexane). MS (ISP): 291.2 (M+H)⁺.
- 18.38 (RS)-1-[1-(4-Pyrrol-1-yl-phenyl)-1H-phthalazin-2-yl]-propenone, (red
25 oil), MS (ISP): 328.2 (M+H)⁺.
- 18.39 (RS)-1-[1-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-1H-phthalazin-2-yl]-propenone, (yellow oil),
- 18.40 (RS)-1-(1-Cyclopropyl-1H-phthalazin-2-yl)-propenone, b.p. 120-125°C/0.08 mbar MS (EI): 226 (M),

- 18.41 (RS)-1-[1-(4-Methylsulfonyl-phenyl)-1H-phthalazin-2-yl]-propenone, m.p. 95-98°C (ethyl acetate/hexane). MS (EI): 308 (M),
- 18.42 (RS)-1-[1-(6-Methyl-pyridin-3-yl)-1H-phthalazin-2-yl]-propenone, m.p. 76-79°C (ethyl acetate/hexane). MS (ISP): 278.2 (M+H)⁺,
- 5 18.43 (RS)-1-(1-[1,3]Dithian-2-yl-1H-phthalazin-2-yl)-propenone, m.p. 140-143°C (ethyl acetate/hexane). MS (ISP): 305.2 (M+H)⁺.
- 18.44 (RS)-1-[1-(6-Dimethylamino-pyridin-3-yl)-1H-phthalazin-2-yl]-propenone, m.p. 125-127°C (ethyl acetate/hexane), MS (ISP): 307.2 (M+H)⁺.
- 18.45 (RS)-1-(1-Pyridin-3-yl-1H-phthalazin-2-yl)-propenone, MS (ISP): 264.3
10 (M+H)⁺.
- 18.46 (RS)-1-(1-Cyclobutyl-1H-phthalazin-2-yl)-propenone, b.p. 120°C/0.05 mbar MS (ISP): 241.4 (M+H)⁺.
- 18.47 (RS)-1-(1-Cyclopentyl-1H-phthalazin-2-yl)-propenone, b.p. 150°C/0.12 mbar MS (EI): 254 (M).
- 15 18.48 (RS)-1-[1-(4-Trifluoromethyl-phenyl)-1H-phthalazin-2-yl]-propenone, m.p. 90-91°C (hexane). MS (ISP): 331.2 (M+H)⁺.
- 18.49 (RS)-1-[1-(5-Chloro-pyridin-2-yl)-1H-phthalazin-2-yl]-propenone, m.p. 131-132°C (ethyl acetate/hexane) MS (ISP): 298.2 (M+H)⁺.
- 18.50 (RS)-1-(1-Cyclohexyl-1H-phthalazin-2-yl)-propenone, b.p. 135°C/0.08
20 mbar MS (EI): 268 (M).
- 18.51 (RS)-1-[1-(4-Methoxy-phenyl)-1H-phthalazin-2-yl]-propenone, b.p. 165°C/0.1 mbar MS (ISP): 293.3 (M+H)⁺.
- 18.52 (RS)-1-[1-(3,4-Dimethoxy-phenyl)-1H-phthalazin-2-yl]-propenone, b.p. 124-125°C (ethyl acetate/hexane) MS (ISP): 323.3 (M+H)⁺.
- 25 18.53 (RS)-1-(1-Benzo[1,3]dioxol-5-yl-1H-phthalazin-2-yl)-propenone, m.p. 98-101°C (ethyl acetate/hexane) MS (EI): 306 (M).
- 18.54 (RS)-4-(2-Acryloyl-1,2-dihydro-phthalazin-1-yl)-benzonitrile,
- 18.55 (RS)-4-(2-Acryloyl-1,2-dihydro-phthalazin-1-yl)-benzoic acid tert-butyl ester,

- 18.56 (RS)-1-(1-Thiophen-2-yl-1H-phthalazin-2-yl)-propenone, (orange oil)
MS (EI): 268 (M).
- 18.57 (RS)-1-[1-(5-Butyl-thiophen-2-yl)-1H-phthalazin-2-yl]-propenone,
(yellow oil) MS (EI): 324 (M).
- 5 18.58 (RS)- 1-{1-[4-(1-Hydroxy-ethyl)-phenyl]-1H-phthalazin-2-yl}-
propenone,
- 18.59 (RS)-1-(1-Benzenesulfonylmethyl-1H-phthalazin-2-yl)-propenone,
m.p. 113-116°C (ethyl acetate/hexane) MS (ISP): 341.1 (M+H)⁺.
- 18.60 (RS)-4-(2-Acryloyl-1,2-dihydro-phthalazin-1-yl)-N,N-dimethyl-
10 benzenesulfonamide, MS (ISP): 370.2 (M+H)⁺.
- 18.61 (RS)-1-[1-(4-Methoxymethyl-phenyl)-1H-phthalazin-2-yl]-propenone,
b.p. 200°C/0.11 mbar MS (ISP): 307.2 (M+H)⁺.
- 18.62 (RS)-1-(1-{4-[(Diisopropylamino)-methyl]-phenyl}-1H-phthalazin-2-
yl)-propenone, m.p. 99-101°C (hexane). MS (ISP): 376.4 (M+H)⁺.
- 15 18.63 (RS)-1-[1-(4-Chloro-phenyl)-1H-phthalazin-2-yl]-propenone, m.p. 71-
72°C (ethyl acetate/hexane). MS (ISP): 297.2 (M+H)⁺.
- 18.64 (RS)-1-[1-(6-Methoxy-pyridin-3-yl)-1H-phthalazin-2-yl]-propenone,
m.p. 128-130°C (ethyl acetate/hexane). MS (ISP): 294.3 (M+H)⁺.
- 18.65 (RS)-1-{1-[4-(4-Methyl-piperazin-1-ylmethyl)-phenyl]-1H-phthalazin-
20 2-yl}-propenone, (yellow oil) MS (ISP): 375.4 (M+H)⁺.
- 18.66 (RS)-1-[1-(4-Morpholin-4-ylmethyl-phenyl)-1H-phthalazin-2-yl]-
propenone, (yellow oil). MS (ISP): 362.2 (M+H)⁺.
- 18.67 (RS)-1-(1-Adamantan-1-yl-1H-phthalazin-2-yl)-propenone, m.p. 157-
158°C (hexane). MS (ISP): 321.3 (M+H)⁺.
- 25 18.68 (RS)-1-[1-[6-(1-Hydroxy-1-methyl-ethyl)-pyridin-3-yl]-1H-phthalazin-2-
yl]-propenone,
- 18.69 (RS)-1-[1-(6-Morpholin-4-yl-pyridin-3-yl)-1H-phthalazin-2-yl]-
propenone, (yellow oil) MS (ISP): 349.4 (M+H)⁺.

18.70 (RS)-5-(2-Acryloyl-1,2-dihydro-phthalazin-1-yl)-pyridin-2-carbonic acid tert-butylamide, MS (EI): 362 (M).

The (+)-enantiomere compounds and (-)-enantiomere compounds respectively, can be prepared from the racemic [1H-Phthalazin-2-yl]-

5 propenone by HPLC (e.g. ChiralCell OD). Thus are obtained:

18.71. S-(+)-(1-Phenyl-1H-phthalazin-2-yl)-propenone; $[\alpha]_D = +724^\circ$ (c=1 ; methanol).

18.72. R-(-)-(1-Phenyl-1H-phthalazin-2-yl)-propenone; $[\alpha]_D = -720^\circ$ (c=1 ; methanol).

10 18.73. R-(+)-(1-Furan-2-yl-1H-phthalazin-2-yl)-propenone; $[\alpha]_D = +638^\circ$ (c=1 ; methanol).

18.74. S-(-)-(1-Furan-2-yl-1H-phthalazin-2-yl)-propenone; $[\alpha]_D = -622^\circ$ (c=1 ; methanol).

18.75. S-(+)-(1-Propyl-1H-phthalazin-2-yl)-propenone ; $[\alpha]_D = +861^\circ$ (c=1 ;
15 methanol).

18.76. R-(-)-(1-Propyl-1H-phthalazin-2-yl)-propenone ; $[\alpha]_D = -902^\circ$ (c=1 ; methanol).

18.77. S-(+)-(1-Methyl-1H-phthalazin-2-yl)-propenone ; $[\alpha]_D = +874^\circ$ (c=1 ; methanol).

20 18.78. R-(-)-(1-Methyl-1H-phthalazin-2-yl)-propenone ; $[\alpha]_D = -903^\circ$ (c=1 ; methanol).

18.79 (E)-(R)-1-[1-(6-Methyl-pyridin-3-yl)-1H-phthalazin-2-yl]-propenone, b.p. 145°C/0.08 mbar, $[\alpha]_D = +571^\circ$ (c=1, methanol). MS (ISP): 278.1 (M+H)⁺.

25 18.80 (E)-(S)-1-[1-(6-Methyl-pyridin-3-yl)-1H-phthalazin-2-yl]-propenone, b.p. 150°C/0.1 mbar, $[\alpha]_D = -536^\circ$ (c=0.8, methanol). MS (ISP): 278.2 (M+H)⁺.

18.81 (R)-1-(1-Cyclopropyl-1H-phthalazin-2-yl)-propenone, b.p. 120°C/0.1 mbar, $[\alpha]_D = +960^\circ$ (c=1, methanol). MS (EI): 226 (M).

18.82 (S)-1-(1-Cyclopropyl-1H-phthalazin-2-yl)-propenone, b.p. 120°C/0.1 mbar , $[\alpha]_D = -958^\circ$ (c=1, methanol). MS (EI): 226 (M).

18.83 (R)-1-[1-(4-Methylsulfanyl-phenyl)-1H-phthalazin-2-yl]-propenone, m.p. 98-104°C, $[\alpha]_D = +623^\circ$ (c=1, chloroform). MS (ISP): 309.1 (M+H)⁺.

18.84 (S)-1-[1-(4-Methylsulfanyl-phenyl)-1H-phthalazin-2-yl]-propenone, m.p. 98-104°C, $[\alpha]_D = -635^\circ$ (c=1, chloroform). MS (EI): 308 (M).

- 5 The compounds of formula III in which R³ is cyclopentanone are prepared as follows:

Example 19

Preparation of (RS)-2-(2-acryloyl-1,2-dihydro-phthalazin-1-yl)-cyclopentanone

- A solution of 317 mg of acryloyl chloride in 1.5 ml of methylene chloride is slowly added dropwise at 0°C to a solution of 390 mg of phthalazine and 536 mg of 1-morpholinocyclopentene in 10 ml of methylene chloride. The mixture is stirred at 0°C for 2 hrs., then concentrated, treated with ice-water and made basic by the addition of sodium carbonate. The mixture is extracted 3 times with ethyl acetate. The organic phases are combined, dried, filtered, the filtrate is concentrated and the residue is chromatographed on 65 g of silica gel; eluent: cyclohexane/ethyl acetate 4:1. 136 mg of (RS)-2-(2-acryloyl-1,2-dihydro-phthalazin-1-yl)-cyclopentanone (mixture of diastereomers) are isolated as a yellowish oil. MS: 268 (M⁺).

- The compounds of formula III in which R³ is cyclohexanone are prepared as follows:

Example 20

Preparation of (RS)-2-(2-acryloyl-1,2-dihydro-phthalazin-1-yl)-cyclohexanone

- A solution of 0.53 ml of acryloyl chloride in 3 ml of methylene chloride is slowly added dropwise at 0°C to a solution of 0.78 g of phthalazine and 1.2 ml of 1-trimethylsiloxy-cyclohexene. After the addition the mixture is stirred at 0°C for a further 30 min., then concentrated, treated with ice-water and made basic by the addition of sodium carbonate. The mixture is extracted 3 times with 100 ml of ethyl acetate each time. The organic phases are combined, dried over magnesium sulphate, filtered and the filtrate is concentrated. 1.63 g of (RS)-2-(2-acryloyl-1,2-dihydro-phthalazin-1-yl)-cyclohexanone (mixture of diastereomers) are isolated as a brownish oil. MS: 282 (M⁺).

The following compounds of formula III are prepared in analogy to Example 20.1.

20.2. (RS)-1-[1-(2-Oxo-propyl)-1H-phthalazin-2-yl]-propenone as a brownish oil. MS : 242 (M^+).

5 20.3. Methyl (RS)-2-(2-acryloyl-1,2-dihydro-phthalazin-1-yl)-2-methyl-propionate as a brownish oil. MS : 286 (M^+).

20.4. (RS)-1-[1-(1-Methyl-2-oxo-2-phenyl-ethyl)-1H-phthalazin-2-yl]-propenone (mixture of diastereomers) as a brownish oil. MS: 318 (M^+).

20.5. (RS)-1-[1-(2-Oxo-2-phenyl-ethyl)-1H-phthalazin-2-yl]-propenone as a
10 yellow oil. MS : 304 (M^+).

20.6. (RS)-3-(2-Acryloyl-1,2-dihydro-phthalazin-1-yl)-tetrahydro-pyran-2-one (mixture of diastereomers) as a yellow foam. MS : 284 (M^+).

20.7. (RS)-1-[1-(2-Furan-2-yl-2-oxo-ethyl)-1H-phthalazin-2-yl]-propenone as a brownish oil. MS: 294 (M^+).

15 The compounds of formula III in which R^3 is hydrogen are prepared as follows:

Example 21

Preparation (sic) of 1-(1H-phthalazin-2-yl)-propenone

A solution of 1 g of phthalazine in 10 ml of methanol is treated at -78°C with
20 290 mg of sodium borohydride and stirred for a further 10 min. A solution of 0.75 g of acryloyl chloride in 5 ml of diethyl ether is added dropwise at -78°C during 45 min. and the pale yellow suspension is stirred at -78°C for a further 1 hr. The mixture is poured on to 50 ml of ice-water, treated with 50 ml of a 10% aqueous sodium carbonate solution and extracted with 3 X
25 50 ml of methylene chloride. The organic phases are combined and washed with 100 ml of water and 50 ml of a saturated aqueous sodium chloride solution. The organic phase is dried over magnesium sulphate, filtered, the filtrate is concentrated and the residue is chromatographed on 80 g of silica gel; eluent: ethyl acetate. 1.22 g of 1-(1H-phthalazin-2-yl)-propenone are
30 isolated as a pale yellow oil. MS: 186 (M^+).

Compounds of formula III in which R³ carries a hydroxyalkyl group are prepared as follows:

Example 22

22.1. Preparation of (E)-(RS)-1-{1-(4-hydroxymethyl-phenyl)-1H-phthalazin-2-yl}-propenone.

A solution of 730 mg of (E)-(RS)-1-{1-(4-tetrahydro-pyran-2-yloxymethyl)-phenyl}-1H-phthalazin-2-yl}-propenone in 20 ml of methanol is treated with a spatula tip of para-toluenesulphonic acid. After two hours the reaction mixture is concentrated and the residue is chromatographed on silica gel. 320 mg of CH₂Cl₂/MeOH/ NH₄OH: 95/5/0.5) are obtained as a colourless oil. MS (EI): 292 (M).

The educt (E)-(RS)-1-{1-(4-tetrahydro-pyran-2-yloxymethyl)-phenyl}-1H-phthalazin-2-yl}-propenone, MS (ISP): 377.3 (M+H)⁺, used in Reaction 22 is prepared by reacting the corresponding 4-tetrahydro-pyran-2-yloxymethyl-phenyl bromide with phthalazine in the presence of butyllithium.

The following compounds of formula III in which R³ carries a hydroxyalkyl group were prepared in analogy to Example 22.1.

22.2. (E)-(RS)-1-{1-(2-Hydroxymethyl-phenyl)-1H-phthalazin-2-yl}-propenone. MS (ISP): 293.2 (M+H)⁺

The educt (E)-(RS)-1-{1-(2-tetrahydro-pyran-2-yloxymethyl)-phenyl}-1H-phthalazin-2-yl}-propenone, MS (ISP): 377.4 (M+H)⁺, is [prepared] from the corresponding 2-tetrahydro-pyran-2-yloxymethyl-phenyl bromide by reaction with butyllithium.

22.3. (E)-(RS)-1-{1-(3-Hydroxymethyl-phenyl)-1H-phthalazin-2-yl}-propenone. MS (ISP): 293.2 (M+H)⁺

The educt (E)-(RS)-1-{1-(3-tetrahydro-pyran-2-yloxymethyl)-phenyl}-1H-phthalazin-2-yl}-propenone, MS (ISP): 377.2 (M+H)⁺, is prepared from the corresponding 1-(3-tetrahydro-pyran-2-yloxymethyl)-phenyl bromide by reaction with butyllithium.

22.4. (E)-(RS)-1-{1-(4-(2-Hydroxyethyl)-phenyl)-1H-phthalazin-2-yl}-propenone. MS(ISP): 307.3 (M+H)⁺

The educt (E)-(RS)-1-{1-[4-(2-tetrahydro-pyran-2-yloxy)-ethyl]-phenyl}-1H-phthalazin-2-yl]-propenone MS (EI): 390 (M), is prepared from the corresponding 1-[4-(2-tetrahydro-pyran-2-yloxy) ethyl]-phenyl bromide by reaction with butyllithium.

- 5 22.5. (E)-(RS)-1-{1-(4-Hydroxybutyl)-1H-phthalazin-2-yl]-propenone, colourless oil, MS (EI): 258 (M).

The educt (E)-(RS)-1-{1-[4-[2-tetrahydro-pyran-2-yloxy]-butyl]-1H-phthalazin-2-yl]-propenone, MS (ISP): 343.3 (M+H)⁺, is prepared from the corresponding Grignard reagent (from 1-[4-(2-tetrahydro-pyran-2-yloxy)-ethyl]-phenyl
10 bromide.

Compounds of formula III in which R³ carries a hydroxy group are prepared as follows:

Example 23

- 23.1. Preparation of (E)-(RS)-1-{1-(4-hydroxy-phenyl)-1H-phthalazin-2-yl]-
15 propenone.

A solution [of] 740 mg of 1-{1-[4-(tert-butyl-dimethylsilanyloxy)-phenyl]-1H-phthalazin-2-yl]-propenone in 20 ml of tetrahydrofuran is treated at about 0°C with 1 ml of 1M tetrabutylammonium fluoride solution. After two hours the solvent is evaporated and the residue, dissolved in ethyl acetate, is
20 washed with water and saturated sodium chloride solution. The organic phase is dried over magnesium sulphate, filtered, the filtrate is concentrated and the residue is chromatographed on silica gel (eluent: ethyl acetate/hexane: 1/1). The pure fractions are combined, concentrated and triturated in hexane. 404 mg of (E)-(RS)-1-{1-(4-hydroxy-phenyl)-1H-phthalazin-2-yl]-
25 propenone are obtained as a white solid. MS (ISP): 279.2 (M+H)⁺

The educt 1-{1-[4-(tert-butyl-dimethylsilanyloxy)-phenyl]-1H-phthalazin-2-yl]-propenone, MS (ISP): 393.4 (M+H)⁺, is prepared from the corresponding 4-tert-butyl-dimethylsilanyloxy)-phenyl bromide by reaction with butyllithium.

- 30 The following compound was prepared in analogy to Example 23.1.:

23.2. bb) (E)-(RS)-1-{1-(3-Hydroxy-phenyl)-1H-phthalazin-2-yl]-propenone. MS (ISP): 279.2 (M+H)⁺

The educt 1-{1-[3-(tert-butyl-dimethylsilanyloxy)-phenyl]-1H-phthalazin-2-yl}-propenone, MS (EI): 392 (M), was prepared from the corresponding 3-(tert-butyl-dimethylsilanyloxy)-phenyl bromide by reaction with butyllithium

Compounds of formula III in which R³ carries a carbamoyl group are
5 prepared as follows:

Example 24

24.1 Preparation of (E)-(RS)-carbamic acid 4-(2-acryloyl-1,2-dihydro-phthalazin-1-yl)-benzyl ester.

A solution of 292 mg of (E)-(RS)-1-{1-(4-hydroxymethyl-phenyl)-1H-phthalazin-2-yl}-propenone in 20 ml of dichloromethane is treated with 282 mg of
10 disuccinyl carbonate and 61 mg of 4-dimethylaminopyridine. After 2 hrs. the solution is diluted with 20 ml of tetrahydrofuran and treated with 0.5 ml of triethylamine sic and 2 ml of saturated sodium chloride solution. After
12 hrs. the solvents are evaporated. The residue is dissolved in
15 dichloromethane and washed with water. The organic phase is dried over magnesium sulphate, filtered, the filtrate is concentrated and the residue is chromatographed on silica gel (eluent: ethyl acetate/hexane: 2/1). The pure fractions are combined, concentrated. 210 mg of white product are obtained.
MS (ISP): 336.2 (M+H)⁺ 353.3 (M+NH₄)⁺

20 The following compounds were prepared in analogy to Example 23.1.:

24.2. (E)-(RS)-Morpholine-1-carbamic acid 4-[4-(2-acryloyl-1,2-dihydro-phthalazin-1-yl)-phenyl]-butyl ester. MS (ISP): 372.3 (M+H)⁺

24.3. (E)-(RS)-Carbamic acid 4-(2-acryloyl-1,2-dihydrophthalazin-1-yl)-butyl ester MS (ISP): 302.2 (M+H)⁺

25 24.4. (E)-(RS)-Carbamic acid 4-(2-acryloyl-1,2-dihydrophthalazin-1-yl)-propyl ester MS (ISP): 288.3 (M+H)⁺

Compounds of formula III in which the R³ carries an aldehyde group are prepared as follows:

Example 25

30 Preparation of (E)-(RS)-3-(2-acryloyl-1,2-dihydro-phthalazin-1-yl)-propionaldehyde

A solution of 500 mg of (E)-(RS)-1-[1-(2-[1,3]-dioxolan-2-yl-ethyl)-1H-phthalazin-2-yl]-propenone in 15 ml of ethanol is treated with 3 ml of 2N HCl. After twenty hours at 60°C the reaction mixture is concentrated and the residue is diluted in ethyl acetate, washed with saturated sodium bicarbonate and saturated sodium chloride solution then dried over magnesium sulphate filtered, the filtrate is concentrated and the residue is chromatographed on silica gel (eluent CH₂Cl₂/ether 95:). 50 mg of material [as a] colourless oil are obtained. MS (EI): 242 (M)

Compounds of formula III in which the R³ carries an alkylhydroxy group can be prepared from the corresponding aldehyde as follows:

Example 26

Preparation [of] (E)-(RS)-1-[1-(3-hydroxy-propyl))-1H-phthalazin-2-yl]-propenone

A solution of 220 mg in 3 ml of ethanol is treated at about 0°C with 13 mg of sodium borohydride. After one hour the solution is concentrated, the residue is diluted with ethyl acetate, washed with saturated sodium bicarbonate and saturated sodium chloride solution then dried over magnesium sulphate, filtered, the filtrate is concentrated and the residue is chromatographed on silica gel (eluent hexane/ether 6:4). 176 mg of material are obtained. MS (EI): 244 (M)

The dihydro-phthalazines of formula IV used for the preparation of compounds III are generally relatively unstable, oxidation-sensitive compounds, which are often reacted directly in the crude state with acryloyl halides. They can be prepared as described hereinafter or in analogy thereto:

Example 27

27.1 Preparation of 1-phenyl-1,2-dihydro-phthalazine

A solution of 4 g of phthalazine in 50 ml of tetrahydrofuran is added dropwise at room temperature to a solution of phenyl-magnesium bromide (prepared from 6 g of bromobenzene and 1 g of magnesium in 30 ml of tetrahydrofuran). The reaction mixture is held at reflux for 6 hrs. After cooling the mixture is treated with a saturated aqueous solution of ammonium chloride and extracted 3 times with diethyl ether. The organic phases are

combined, dried and subsequently triturated with pentane. 2.32 g of not quite pure 1-phenyl-1,2-dihydro-phthalazine are isolated as a yellowish solid, m.p. 79°C.

The following compounds of formula IV are prepared in analogy to Example

5 27.1.

27.2. 1-Pyridin-2-yl-1,2-dihydro-phthalazine as a brownish oil MS : 208 (M⁺).

27.3. 1-Thiazol-2-yl-1,2-dihydro-phthalazine as a brownish oil.

27.4. 1-Butyl-1,2-dihydro-phthalazine as a brownish oil.

10 27.5 1-(5-Methyl-pyridin-2-yl)-1,2-dihydro-phthalazine as a dark impure oil.

27.6. (RS)-1-(2,4-Difluoro-phenyl)-1,2-dihydro-phthalazine as a reddish oil. MS: 245 (M + H)⁺.

27.7. (RS)-1-Cyclobutyl-1,2-dihydro-phthalazine m.p. 64-68°C (hexane). MS (ISP): 187.3 (M+H)⁺.

15 27.8. (RS)-1-Cyclopentyl-1,2-dihydro-phthalazine, brown solid

27.9. (RS)-1-Cyclohexyl-1,2-dihydro-phthalazine, m.p. 122-124°C (hexane), MS (ISP): 215.4 (M+H)⁺.

Example 28

28.1. Preparation of 1-furan-2-yl-1,2-dihydrophthalazine

20 22.5 ml of an about 1.6M solution of butyllithium are slowly added dropwise at -78°C to a solution of 2.46 g of furan in 30 ml of tetrahydrofuran. The mixture is stirred at -78°C for 20 min., then at -20°C for 2 hrs. The solution is again cooled to -78°C and treated slowly with a solution of 4.68 g of phthalazine in 36 ml of tetrahydrofuran. The mixture is stirred at -78°C for
25 2 hrs., then poured on to about 500 ml of ice-water and extracted 4 times with 150 ml of ethyl acetate each time. The organic phases are dried, concentrated and the residue is chromatographed immediately on 120 g of silica gel; eluent: hexane/ethyl acetate 3:7. 4.08 g of dark, impure 1-furan-2-yl-1,2-dihydrophthalazine are isolated.

The following compounds of formula IV are prepared in analogy to Example 28.1.:

- 28.2. 2-(1,2-Dihydro-phthalazin-1-yl)-N,N-dimethyl-benzenesulphonamide as an impure, dark oil, MS: 315 (M^+).
- 5 28.3. [2-(1,2-Dihydro-phthalazin-1-yl)-benzyl]-dimethyl-amine as a dark, very unstable oil.
- 28.4. (RS)- 1-Methylsulfanylmethyl-1H-phthalazine as an impure, yellow oil,
- 28.5. (RS)- 1-(4-tert-Butyl-phenyl)-1H-phthalazine as an impure, yellow oil,
- 10 28.6. (RS)- 1-p-Tolyl-1H-phthalazine as an impure, yellow oil,
- 28.7. (RS)- 1-(4-Ethyl-phenyl)-1H-phthalazine as an impure, yellow oil,
- 28.8. (RS)- 1-(4-Trifluoromethoxy-phenyl)-1H-phthalazine as an impure, yellow oil,
- 28.9. (RS)- 1-(3,4-Dimethyl-phenyl)-1H-phthalazine as an impure, yellow
15 oil,
- 28.10. (RS)- 1-tert-Butyl-1H-phthalazine as an impure, yellow oil,
- 28.11. (RS)- 1-(5,6-Dihydro-4H-pyran-2-yl)-1H-phthalazine MS (ISP): 213.3 ($M+H$)⁺.
- 28.12. (RS)- 1-(2,4,6-Trimethyl-phenyl)-1H-phthalazine as an impure,
20 yellow oil,
- 28.13 (RS)-1-Biphenyl-4-yl-1,2-dihydro-phthalazine, yellow oil,
- 28.14 (RS)-1-[1-[4-[1-Ethoxy-ethoxy]-phenyl]-1H-phthalazine, yellow oil,
- 28.15 (RS)-1-Bicyclo[2.2.1]hept-2endo- and/or 2exo 2-yl-1,2-dihydro-phthalazine, brown oil,
- 25 28.16 (RS)-1-(6-Methyl-pyridin-2-yl)-1,2-dihydro-phthalazine, yellow oil,
- 28.17 (RS)-[4-(1,2-Dihydro-phthalazin-1-yl)-phenyl]-dimethyl-amine, yellow oil,

- 28.18 (RS)-1-[4-(2-Ethoxy-ethoxy)-phenyl]-1,2-dihydro-phthalazine, m.p. 129-131°C (acetylacetate/hexane). MS (EI): 296 (M).
- 28.19 (RS)-1-m-Tolyl-1,2-dihydro-phthalazine, brown oil
- 28.20 (RS)-1-(3,5-Dimethyl-phenyl)-1,2-dihydro-phthalazine, m.p. 102-
5 107°C (hexane). MS (ISP): 237.3 (M+H)⁺.
- 28.21 (RS)-1-(4-Pyrrol-1-yl-phenyl)-1,2-dihydro-phthalazine, m.p. 129-130°C (toluol/hexane). MS (ISP): 274.3 (M+H)⁺.
- 28.22 (RS)-1-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-1,2-dihydro-phthalazine, yellow oil,
- 10 28.23 (RS)-1-Cyclopropyl-1,2-dihydro-phthalazine, yellow oil,
- 28.24 (RS)-1-(4-Methylsulfanyl-phenyl)-1,2-dihydro-phthalazine, m.p. 120-123°C (acetylacetate/hexane), MS (ISP): 255.2 (M+H)⁺.
- 28.25 (RS)-1-(6-Methyl-pyridin-3-yl)-1,2-dihydro-phthalazine, yellow oil.
- 28.26 (RS)-1-[1,3]Dithian-2-yl-1,2-dihydro-phthalazine, m.p. 134-136°C
15 (diisopropylether). MS (ISP): 251.1 (M+H)⁺.
- 28.27 (RS)-[5-(1,2-Dihydro-phthalazin-1-yl)-pyridin-2-yl]-dimethyl-amine, m.p. 124-127°C (acetylacetate/hexane). MS (ISP): 253.2 (M+H)⁺.
- 28.28 (RS)-1-Pyridin-3-yl-1,2-dihydro-phthalazine,
- 28.29 (RS)-1-(4-Trifluoromethyl-phenyl)-1,2-dihydro-phthalazine,
- 20 28.30 (RS)-1-(5-Chloro-pyridin-2-yl)-1,2-dihydro-phthalazine,
- 28.31 (RS)-1-(4-Methoxy-phenyl)-1,2-dihydro-phthalazine, m.p. 121-125°C (acetylacetate/hexane). MS (EI): 238 (M).
- 28.32 (RS)-1-(3,4-Dimethoxy-phenyl)-1,2-dihydro-phthalazine, brown oil,
- 28.33 (RS)-1-Benzo[1,3]dioxol-5-yl-1,2-dihydro-phthalazine, m.p. 102-104°C
25 (acetylacetate/hexane). MS (ISP): 253.2 (M+H)⁺.
- 28.34 (RS)-4-(1,2-Dihydro-phthalazin-1-yl)-benzonitrile, red oil,
- 28.35 (RS)-4-(1,2-Dihydro-phthalazin-1-yl)-benzoic acid tert-butyl ester,

- 28.36 (RS)-1-Thiophen-2-yl-1,2-dihydro-phthalazine,
- 28.37 1-[4-(1,2-Dihydro-phthalazin-1-yl)-phenyl]-ethanol, m.p. 133-134°C (acetylacetate/hexane). MS (ISP): 253.2 (M+H)⁺.
- 28.38 (RS)-1-Benzenesulfonylmethyl-1,2-dihydro-phthalazine, orange oil.
- 5 28.39 (RS)-4-(1,2-Dihydro-phthalazin-1-yl)-N,N-dimethyl-benzene-sulfonamide,
- 28.40 (RS)-1-(4-Methoxymethyl-phenyl)-1,2-dihydro-phthalazine, brown oil,
- 28.41 (RS)-[4-(1,2-Dihydro-phthalazin-1-yl)-benzyl]-diisopropyl-amine, brown oil,
- 10 28.42 (RS)-1-(4-Chloro-phenyl)-1,2-dihydro-phthalazine, m.p. 97-98°C (hexane), MS (EI): 242 (M).
- 28.43 (RS)-1-(6-Methoxy-pyridin-3-yl)-1,2-dihydro-phthalazine,
- 28.44 (RS)-1-[4-(4-Methyl-piperazin-1-ylmethyl)-phenyl]-1,2-dihydro-phthalazine, yellow oil,
- 15 28.45 (RS)-1-(4-Morpholin-4-ylmethyl-phenyl)-1,2-dihydro-phthalazine, brown oil,
- 28.46 (RS)-1-Adamantan-1-yl-1,2-dihydro-phthalazine, m.p. 170-172°C, dec. (hexane). MS (ISP): 267.4 (M+H)⁺.
- 28.47 (RS)-1-(6-Morpholin-4-yl-pyridin-3-yl)-1,2-dihydro-phthalazine, m.p. 20 167°C (acetylacetate). MS (ISP): 295.3 (M+H)⁺.

Example 29

Preparation of (RS)-1-(4-fluoro-phenyl)-1,2-dihydro-phthalazine

- 5.53 ml of a 1.6 M solution of butyllithium in hexane are added dropwise at -78°C within 20 min. to a solution of 1.48 g of 1-bromo-4-fluoro-benzene in
- 25 5 ml of tetrahydrofuran. The resulting white suspension is stirred for a further hour. A solution of 1 g of phthalazine in 5 ml of tetrahydrofuran is added dropwise at -78°C within 10 min. The reaction mixture is left to warm to room temperature, treated with 50 ml of water and extracted 3 times with 50 ml of dichloromethane each time. The organic phases are combined

washed with 50 ml of water and 50 ml of a saturated sodium chloride solution, dried over magnesium sulphate, filtered, the filtrate is concentrated and the residue is chromatographed on 100 g of silica gel with the eluent hexane/ethyl acetate 1:1. 1.49 g (86%) of (RS)-1-(4-fluoro-phenyl)-1,2-dihydro-phthalazine are obtained as a yellow oil. MS: 227 (M+H)⁺.

Example 30

Preparation of (RS)-1-benzenesulphinylmethyl-1,2-dihydro-phthalazine

A solution of 1 g of methyl phenyl sulfoxide in 14 ml of tetrahydrofuran is added dropwise at 78°C within 10 min. to 3.93 ml of 2M solution of lithium diisopropylamide in tetrahydrofuran/heptane/ethylbenzene in 20 ml of tetrahydrofuran. The reaction mixture is stirred for a further 30 min. A solution of 0.928 g of phthalazine in 14 ml of tetrahydrofuran is added dropwise within 10 min. The mixture is stirred at -78°C for 1 hr., treated with 100 ml of water and extracted 3 times with 50 ml of chloroform. The organic phases are combined, dried over magnesium sulphate, filtered and the filtrate is concentrated. 1.9 g of crude (RS)-1-benzenesulphinylmethyl-1,2-dihydro-phthalazine are isolated as a yellowish oil, MS(ISP): 271.2 (M+H)⁺.

Example 31

Preparation of (RS)-1-(6-Methyl-pyridin-3-yl)-1,2-dihydro-phthalazine

15.3 ml of a 1.6 M solution of butyllithium in hexane are added dropwise at -78°C within 20 min. to a solution of 5.68 g 2,5-dibromo-pyridine in 200 ml diethylether. Under stirring at -78°C the following solutions are added dropwise:

a solution of 2.6 g phthalazine in 100 ml tetrahydrofuran within 15 min., 16.9 ml of a 1.6 M solution of butyllithium in hexane within 5 min. and 2.24 ml methyl iodide.

The reaction mixture is stirred for a further 30 min and treated with 100 ml water and 100 ml of a saturated sodium chloride solution. The organic phases are combined, dried over sodium sulphate and concentrated. 5.4 g (RS)-1-(6-methyl-pyridin-3-yl)-1,2-dihydro-phthalazine are obtained as yellow oil.

The following compounds are prepared in analogy to the preparation of (RS)-1-(6-Methyl-pyridin-3-yl)-1,2-dihydro-phthalazine, as described above.

- 31.1 (RS)-2-[5-(1,2-Dihydro-phthalazin-1-yl)-pyridin-2-yl]-propan-2-ol, brown solid.
- 5 31.2. (RS)-5-(1,2-Dihydro-phthalazin-1-yl)-pyridin-2-carbonic acid tert-butylamide, brown solid. .

Example 32

Preparation of (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-(6-methylsulfanyl-pyridin-3-yl)-1H-phthalazin-2-yl]-
10 propenone

8. 93 ml of a 1.6 M solution of butyllithium in hexane are added dropwise at -78°C within 20 min. to a solution of 2.86 g 5-bromo-2-methyl-sulfanyl-pyridine in 50 ml diethylether. Under stirring at -78°C are a solution of 1.56 g phthalazine in 50 ml tetrahydrofuran is added dropwise
15 within 15 min. (solution A)

15.75 ml of a 1.6 M solution of butyllithium in hexane are added dropwise at -78°C within 10 min. to a solution of 4.3 g (E)-3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-acrylacid ethyl ester in 430 ml tetrahydrofuran. Solution A is added. The reaction mixture is stirred for a
20 further 3 h. The temperature raises up to -10°C. 150 ml water and 100 ml of a saturated sodium chloride solution are added. The organic phases are combined, dried over sodium sulphate and concentrated and the residue is chromatographed on silica gel; eluent: methylenchlorid/methanol/25% ammoniak 95:5:0.5). The pure fractions are combined, concentrated and
25 crystallized from ethanol. 2.9 g (E)-(RS)-3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-(6-methylsulfanyl-pyridin-3-yl)-1H-phthalazin-2-yl]-propenone are isolated, m.p. 142-145°C. MS (ISP): 568.3 (M+H)⁺.

The following compounds are prepared in analogy to the preparation
30 of (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-(6-methylsulfanyl-pyridin-3-yl)-1H-phthalazin-2-yl]-propenone.

- 32.1 (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-(4-methyl-pyridin-2-yl)-1H-phthalazin-2-yl]-propenone, m.p. 149-154°C (methanol). MS (ISP): 536.4 (M+H)⁺.
- 32.2 (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-(2-methyl-pyridin-3-yl)-1H-phthalazin-2-yl]-propenone, m.p. 150-155°C (acetonitrile). MS (ISP): 536.3 (M+H)⁺.
- 32.3 (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-(3-methoxy-phenyl)-1H-phthalazin-2-yl]-propenone, m.p. 114-118°C (methanol). MS (ISP): 551.3 (M+H)⁺.
- 10 32.4 (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-(2-methyl-pyridin-4-yl)-1H-phthalazin-2-yl]-propenone, m.p. 120°C (ethanol). MS (ISP): 536.3 (M+H)⁺.
- 32.5 (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-(2-methyl-pyrimidin-5-yl)-1H-phthalazin-2-yl]-propenone, m.p. 15 142-145°C (methanol). MS (ISP): 537.4 (M+H)⁺.
- 32.6 (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-(3,4,5-trimethoxy-phenyl)-1H-phthalazin-2-yl]-propenone, m.p. 190-196°C (methanol). MS (ISP): 611.3 (M+H)⁺.
- 32.7 (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-(6-hydroxymethyl-pyridin-3-yl)-1H-phthalazin-2-yl]-propenone, 20 m.p. 133-136°C (methanol). MS (EI): 551 (M).
- 32.8 (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-(1-pyridin-4-yl-1H-phthalazin-2-yl)-propenone, m.p. 145-149°C (acetonitrile). MS (ISP): 522.2 (M+H)⁺.
- 25 32.9 (E)-(RS)-1-[1-(6-Bromo-pyridin-3-yl)-1H-phthalazin-2-yl]-3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-propenone, m.p. 132-138°C (methanol). MS (ISP): 602.1 (M+H)⁺.
- 32.10 (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-(2,4-dimethoxy-pyrimidin-5-yl)-1H-phthalazin-2-yl]-propenone, 30 m.p. 160-165°C (methanol). MS (ISP): 583.3 (M+H)⁺.

- 32.11 (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-[4-(2-hydroxy-ethoxy)-phenyl]-1H-phthalazin-2-yl]-propenone, m.p. 169-172°C (methanol). MS (ISP): 581.5 (M+H)⁺.
- 32.12 (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-(4-methoxy-pyridin-2-yl)-1H-phthalazin-2-yl]-propenone, m.p. 125-133°C (ethanol). MS (ISP): 552.2 (M+H)⁺.
- 32.13 (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-(1-[1,3]dioxolo[4,5-b]pyridin-6-yl)-1H-phthalazin-2-yl)-propenone, m.p. 135-140°C (ethanol). MS (ISP): 566.2 (M+H)⁺.
- 10 32.14 (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-[6-(2-hydroxy-ethoxy)-pyridin-3-yl]-1H-phthalazin-2-yl]-propenone, m.p. 212-217°C (methanol). MS (ISP): 582.1 (M+H)⁺.
- 32.15 (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-[6-(2-methoxy-ethoxy)-pyridin-3-yl]-1H-phthalazin-2-yl]-propenone, m.p. 147-151°C (methanol). MS (ISP): 596.2 (M+H)⁺.
- 15 32.16 (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-[6-[2-(2-methoxy-ethoxy)-ethoxy]-pyridin-3-yl]-1H-phthalazin-2-yl]-propenone, m.p. 136-140°C (ethanol). MS (ISP): 640.4 (M+H)⁺.
- 32.17 (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-[6-(3-hydroxy-propoxy)-pyridin-3-yl]-1H-phthalazin-2-yl]-propenone, m.p. 173-178°C (methanol). MS (ISP): 596.2 (M+H)⁺.
- 20 32.18 1-[1-(6-Benzoyloxy-pyridin-3-yl)-1H-phthalazin-2-yl]-3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-propenone, m.p. 136-143°C (ethanol). MS (ISP): 628.2 (M+H)⁺.
- 25 32.19 3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-[6-(2-morpholin-4-yl-ethoxy)-pyridin-3-yl]-1H-phthalazin-2-yl]-propenone, m.p. 120-124°C (ethanol). MS (ISP): 651.2 (M+H)⁺.
- 32.20 3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-[6-(2-dimethylamino-ethoxy)-pyridin-3-yl]-1H-phthalazin-2-yl]-propenone, m.p. 110-114°C (ethanol/water). MS (ISP): 609.2 (M+H)⁺.
- 30

32.21 (E)-(RS)-1-[1-(6-Chloro-pyridin-3-yl)-1H-phthalazin-2-yl]-3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-propenone, m.p. 129-140°C (methanol). MS (ISP): 556.1 (M+H)⁺.

The starting material used above are prepared as follows:

5

Example 33

Preparation of 5-Bromo-2-(2-methoxy-ethoxy)-pyridine

1.1 g sodium and 2.5 g 2,5-dibromo-pyridine are added to 50 ml 2-methoxy-ethanol. The reaction mixture is heated to 90°C and stirred for a further 2.5 hrs, then poured onto 75 ml of a saturated sodiumhydrogen
10 carbonate solution and extracted three times with methylenchloride. The organic phases are combined, dried over sodium sulphate and concentrated and the residue is distilled. 2.2 g 5-Bromo-2-(2-methoxy-ethoxy)-pyridine are obtained., bp. 135°C/0.1 mbar MS (EI): 231 (M).

The following compounds are prepared in analogy to the preparation
15 of 5-bromo-2-(2-methoxy-ethoxy)-pyridine.

33.1. 2-(5-Bromo-pyridin-2-yloxy)-ethanol, m.p. 60°C (hexane). MS (EI): 217 (M).

33.2 5-Bromo-2-[2-(2-methoxy-ethoxy)-ethoxy]-pyridine, b.p. 130°C/1 mbar MS (EI): 276 (M+H)⁺.

20 33.3 3-(5-Bromo-pyridin-2-yloxy)-propan-1-ol, m.p. 58°C (hexane). MS (EI): 231 (M).

33.4 4-[2-(5-Bromo-pyridin-2-yloxy)-ethyl]-morpholine, b.p. 130°C/0.2 mbar

33.5 [2-(5-Bromo-pyridin-2-yloxy)-ethyl]-dimethyl-amine, b.p. 100°C/0.16 mbar MS (ISP): 247.1 (M+H)⁺.

25

Example 34

Preparation of (E)-(RS)-5-(2-{3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-acryloyl}-1,2-dihydro-phthalazin-1-yl)-pyridin-2-carbonic acid amide

15.3 ml of a 1.6 M solution of butyllithium in hexane are added dropwise
30 at -78°C within 15 min. to a solution of 5.68 g 2,5-dibromo-pyridine in 200 ml

of diethylether. The reaction mixture is stirred at -78°C for 10 min. Then a solution of 2.6 g phthalazine in 100 ml tetrahydrofuran is added. The reaction mixture is stirred at -78°C for a further 10 min. Then 20.5 ml of a 1.6 M solution of butyllithium in hexane are added dropwise at -78°C within 10 min. 5 ml trimethylsilylisocyanat are added. The reaction mixture is stirred for a further 20 min. The temperature raises up to -25°C (solution A).

26.2 ml of a 1.6 M solution of butyllithium in hexane are added dropwise at -78°C within 10 min to a solution of 7.16 g (E)-3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-acrylacid ethyl ester in 750 ml tetrahydrofuran. Solution A is added. The reaction mixture is stirred for a further 5.5 h. The temperature raises up to -18°C. 200 ml water and 300 ml of a saturated sodium chloride solution are added. The organic phases are combined, dried over sodium sulphate and concentrated and the residue is chromatographed on silica gel; eluent: methylenchlorid/methanol/25% ammoniak 95:5:0.5). The pure fractions are combined, concentrated and crystallized from ethanol. After recrystallization from ethanol 0.84 g (E)-(RS)-5-(2-{3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-acryloyl}-1,2-dihydro-phthalazin-1-yl)-pyridin-2-carbonsäure amide are obtained; m.p. 204-209°C (Ethanol). MS (ISP): 565.3 (M+H)⁺.

The following compounds are prepared in analogy to the preparation of (E)-(RS)-5-(2-{3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-acryloyl}-1,2-dihydro-phthalazin-1-yl)-pyridin-2-carbonsäure amide

34.1 (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-(6-ethyl-pyridin-3-yl)-1H-phthalazin-2-yl]-propenone, m.p. 124-130°C (ethanol). MS (ISP): 550.2 (M+H)⁺.

Pharmaceutical preparations can be produced in a manner known per se according to the following formulations:

Example A

30 Tablets:

| | |
|--|--------|
| Sulfamethoxazole | 400 mg |
| Compound of formula I, e.g. (E)-(RS)-3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-(1-phenyl-1H-phthalazin-2-yl)-propenone | 80 mg |

| | |
|-------------------------------------|-------------|
| PRIMOJEL (starch derivative) | 6 mg |
| POVIDONE K30 (polyvinylpyrrolidone) | 8 mg |
| Magnesium stearate | <u>6 mg</u> |
| Total weight | 500 mg |

5 Example BTablets:

| | |
|--|-------------|
| Compound of formula I, e.g. (E)-(RS)-3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-(1-furan-2-yl-1H-phthalazin-2-yl)-propenone | 100 mg |
| 10 Corn starch | 15 mg |
| Talc | 3 mg |
| Magnesium stearate | <u>2 mg</u> |
| | 120 mg |

Example C15 Injection solutions:


| | |
|---|-----------|
| Compound of formula I, e.g. E)-(RS)-3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-(1-propyl-1H-phthalazin-2-yl)-propenone | 5 mg |
| Glycofurol 75 | 0.2 ml |
| 20 Aq. bidist. sterile | ad 1.0 ml |

Example DInjection solutions:

| | |
|---|-----------|
| Compound of formula I, e.g. E)-(RS)-3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-(1-propyl-1H-phthalazin-2-yl)-propenone | 5 mg |
| 25 Propylene glycol | 0.5 ml |
| Aq. bidist. sterile | ad 1.0 ml |

Claims

1. Compounds of the general formula



wherein

- 5 R^1 signifies lower-alkoxy;
 R^2 signifies hydroxy or lower-alkoxy;
 R^3 signifies hydrogen, cyano, lower-alkyl, alkenyl, cycloalkyl,
 bicycyl, aryl, heterocyclyl, heteroaryl, aralkyl, aryl-Q-
 alkyl, heterocyclalkyl or a group of the formula-
 10 $CR^4R^4COR^5$;
 Q signifies -SO- or SO_2 ;
 R^4, R^4 each independently signify hydrogen, alkyl, aryl or
 heterocyclyl;
 R^5 signifies hydrogen, alkyl, alkoxy, aryl or heterocyclyl, or
 15 R^4 and R^5 together can form a group $-(CH_2)_n-$, and
 n is a whole number of 2-5,

as well as pharmaceutically usable salts thereof.

2. Compounds according to claim 1, characterized in that R^1 and R^2 signify lower-alkoxy.

20 3. Compounds according to claim 1 or 2, characterized in that R^3 lower alkyl or substituted lower alkyl.

4. Compounds according to claim 1 or 2, characterized in that R^3 signifies phenyl, or substituted phenyl.

25 5. Compounds according to claim 1 or 2, characterized in that R^3 signifies furyl, pyridyl, pyrimidinyl, substituted pyridyl or substituted pyrimidinyl.


6. The compounds

- (E)-(RS)-3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-(1-phenyl-1H-phthalazin-2-yl)-propenone;
 (E)-(RS)-3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-(1-furan-2-yl-1H-phthalazin-2-yl)-propenone;
 (E)-(RS)-3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-(4-hydroxymethyl-phenyl)-1H-phthalazin-2-yl]-propenone;
 (E)-(RS)-3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-(4-hydroxy-phenyl)-1H-phthalazin-2-yl]-propenone;
 (E)-(RS)-3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-(1-ethyl-1H-phthalazin-2-yl)-propenone;
 (E)-(RS)-3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-(4-hydroxy-butyl)-1H-phthalazin-2-yl]-propenone;
 (E)-(R)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-(6-methyl-pyridin-3-yl)-1H-phthalazin-2-yl]-propenone;
 (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-(6-methyl-pyridin-3-yl)-1H-phthalazin-2-yl]-propenone;
 (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-(6-ethyl-pyridin-3-yl)-1H-phthalazin-2-yl]-propenone;
 (E)-(RS)-3-[5-(2,4-Diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-[1-(2-methyl-pyrimidin-5-yl)-1H-phthalazin-2-yl]-propenone;
 as well as pharmaceutically usable salts of these compounds.

7. Compounds according to any one of claims 1-6 for use as medicaments.

8. A process for the manufacture of the compounds in accordance with any one of claims 1-6, characterized by


(a) reacting a compound of the general formula



II

- wherein R¹ and R² are as defined in claim 1 and Y signifies a leaving group,

with a compound of the general formula




III

wherein R^3 is as defined in claim 1,

or

- 5 (b) reacting a phthalazine with a silyl enol ether of formula V or an enamine of formula VI in the presence of a reactive acrylic acid derivative:



III

wherein

- 10 $R^4, R^{4'}$ each independently signify hydrogen, alkyl, aryl or heterocyclyl,
- R^5 , signifies hydrogen, alkyl, alkoxy, aryl or heterocyclyl, or
- R^4 and R^5 together can form a group $-(CH_2)_n-$,
- 15 n is a whole number of 2 to 5,
- R^6-R^7 signify lower alkyl.
- and R^6 and R^7 in the case of enamines of formula VI can also together form a ring.
- 20 X signifies a halogen atom, preferably chlorine or bromine.

9. A medicament containing a compound according to any one of claims 1-6 and a therapeutically inert carrier.
10. A pharmaceutical preparation containing a compound of formula I and a sulphonamide as well as usual pharmaceutical carrier materials.
- 5 11. A preparation according to claim 10 containing a compound of formula I and a sulphonamide in the ratio of preferred ratio being 1:10 to 1:2 parts by weight.
12. Use of compounds of formula I and a sulphonamide for the production of pharmaceutical preparations for the treatment of infections.
- 10 13. Use of compounds according to any one of claims 1-6 as medicaments, especially in infectious diseases.
14. Use of compounds according any one of claims 1-6 in the production of antibioticly-active medicaments.

INTERNATIONAL SEARCH REPORT

national Application No
PCT/EP 98/01051

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D403/10 A61K31/505 C07D405/14 C07D403/14 C07D401/14

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|-----------------------|
| P, Y | WO 97 43277 A (F. HOFFMANN-LA ROCHE AG; SWITZ.) 20 November 1997 see the whole document, especially examples | 1-14 |
| Y | WO 96 16046 A (F. HOFFMANN-LA ROCHE AG; SWITZ.) 30 May 1996 see the whole application, especially examples and definition of heteroaryl for R30 | 1-14 |
| A | B. ROTH ET AL: "2,4-Diamino-5-benzylpyrimidines as Antibacterial agents" JOURNAL OF MEDICINAL CHEMISTRY, vol. 32, no. 8, 1989, pages 1949-1958, XP002068896 see whole document, especially Table 1. | 1-14 |

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Z" document member of the same patent family

Date of the actual completion of the international search

22 June 1998

Date of mailing of the international search report

05/08/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5918 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 851 epo rd,
Fax: (+31-70) 340-3016

Authorized officer

Scruton-Evans, I

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 98/01051

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|---|---------------------|----------------------------|---------------------|
| WO 9743277 A | 20-11-1997 | AU 2894297 A | 05-12-1997 |
| WO 9616046 A | 30-05-1996 | AU 4116196 A | 17-06-1996 |
| | | CZ 9701575 A | 17-09-1997 |
| | | EP 0793656 A | 10-09-1997 |
| | | FI 972194 A | 22-05-1997 |
| | | HU 77372 A | 30-03-1998 |
| | | NO 972393 A | 29-05-1997 |
| | | PL 320458 A | 29-09-1997 |
| | | US 5763450 A | 09-06-1998 |